Aztreonam-Avibactam 
C3601006Final Protocol Amendment 1, 14 July 2021
PFIZER CONFIDENTIAL
Page 1
AN OPEN-LABEL, PARALLEL-GROUP, PHARMACOKINETIC STUDY OF 
MULTIPLE INTRAVENOUS DOSES OF AZTREONAM AND AVIBACTAM IN 
SUBJECTS WITH SEVERE RENAL IMPAIRMENT AND NORMAL RENAL 
FUNCTION
Investigational Product Number: PF-06947387
Investigational Product Name: Aztreonam-Avibactam
United States (US) Investigational New 
Drug (IND) Number:
European Clinical Trials Database 
(EudraCT) Number:Not Applicable (N/A)
Protocol Number: C3601006
Phase: 1
This document and accompanying materials contain confidential information belonging to Pfizer.  Except as 
otherwise agreed to in writing, by accepting or reviewing these documents, you agree to hold this information in 
confidence and not copy or disclose it to others (except where required by applicable law) or use it for 
unauthorized purposes.  In the event of any actual or suspected breach of this obligation, Pfizer must be 
promptly notified.CCI
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 2Document History
Document Version Date Summary of Changes and Rationale
Amen dment 1 14 July 2021 Addition of an exploratory objective : To 
determi neconcordance/comparability of 
capillary microsample plasma 
concentration swith venous plasma
concentratio nsforaztreonam and 
avibac tamin health y subjects with normal 
renal function (Cohort 1) .
Rationale : To facili tate col lection of lower 
blood volume sfor PK samples in planned 
ATM -AVI pediatric protocols, a capillary  
microsampling technique will be evaluated 
for feasibility  and performance in the 
healthy  volunteer cohort with normal renal 
function.
Adde d “temporally ”as amethod for 
measuring t emperature , and changed the 
source of pregnancy  tests kits from 
“provided b y the central laboratory ”to 
“provided b y the investigat orsite”,
change scommunicated to the investig ator 
site in a P ACL dated 07 August 2020 .
Original p rotocol 13June 2018 N/A
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 3TABLE OF CONTENTS
LIST OF TABLES ................................ ................................ ................................ ..................... 6
APPENDI CES ................................ ................................ ................................ ........................... 6
SCHEDULE OF ACTIVI TIES................................ ................................ ................................ ..7
1. INTRODUCTION ................................ ................................ ................................ ............... 12
1.1. Mechanism of Action/I ndica tion................................ ................................ ............. 12
1.2. Background ................................ ................................ ................................ ............. 12
1.3. Rationale ................................ ................................ ................................ .................. 15
1.3.1. Study  Ration ale................................ ................................ ........................... 15
1.3.2. Dose Rationa le................................ ................................ ............................ 15
2. STUDY OBJECTIVES AND ENDPOINTS ................................ ................................ .......17
3. STUDY DESIGN ................................ ................................ ................................ ................. 18
3.1. Study  Overview ................................ ................................ ................................ .......18
4. SUBJECT ELIGIBILI TY CRI TERIA ................................ ................................ ................. 20
4.1. I nclusion Criteria ................................ ................................ ................................ .....20
4.1.1. Specific Requirements for Healthy  Subjects with Normal Renal 
Function ................................ ................................ ................................ ........... 21
4.1.2. Specific Requirements for Subjects with Severe Renal I mpairment .......... 21
4.2. Exclusion Criteria ................................ ................................ ................................ ....22
4.3. L ifesty le Requirements ................................ ................................ ........................... 24
4.3.1. Meals and Dietary Restrictions ................................ ................................ ...24
4.3.2. Alcohol, Caffeine, and Tobacco ................................ ................................ .25
4.3.3. Activity ................................ ................................ ................................ .......25
4.3.4. Contraception ................................ ................................ .............................. 25
4.4. Sponsor’s Qualified Medical Personnel ................................ ................................ ..27
5. STUDY TREATMENTS ................................ ................................ ................................ .....27
5.1. Allocation to Treatment ................................ ................................ .......................... 27
5.2. Subject Compliance ................................ ................................ ................................ .27
5.3. I nvestigational Produc tSupplies ................................ ................................ ............. 27
5.3.1. Dosage Form and Packaging ................................ ................................ ......27
5.3.2. Preparation and Dispensing ................................ ................................ ........ 28
5.4. Administ ration ................................ ................................ ................................ ......... 28
Aztreonam-Avibactam 
C3601006Final Protocol Amendment 1, 14 July 2021
PFIZER CONFIDENTIAL
Page 45.5. Investigational Product Storage ..............................................................................29
5.6. Investigational Product Accountability...................................................................30
5.6.1. Destruction of Investigational Product Supplies ........................................30
5.7. Concomitant Treatment(s).......................................................................................30
6. STUDY PROCEDURES .....................................................................................................31
6.1. Screening................................................................................................................. 31
6.2. Study Period ............................................................................................................33
6.2.1. Day -2 .........................................................................................................336.2.2. Day -1 .........................................................................................................346.2.3. Day 1...........................................................................................................346.2.4. Day 2...........................................................................................................356.2.5. Day 3...........................................................................................................366.2.6. Day 4 (end of trial [EOT])..........................................................................37
6.3. Follow-up ................................................................................................................3 8
6.3.1. Follow-up Contact ......................................................................................38
6.4. Subject Withdrawal .................................................................................................38
7. ASSESSMENTS................................................................................................................. .39
7.1. Safety.................................................................................................................... ...39
7.1.1. Laboratory  Tests .........................................................................................39
7.1.2. Pregnancy Testing ......................................................................................407.1.3. Physical Examinations................................................................................417.1.4. Blood Pressure and Pulse Rate ...................................................................417.1.5. Temperature................................................................................................427.1.6. Electrocardiogram.......................................................................................42
7.2. Pharmacokinetics ....................................................................................................42
7.2.1. Plasma for Analysis of Aztreonam-Avibactam ..........................................427.2.2. Urine for Analysis of Aztreonam-Avibactam.............................................43
7.3. Blood Volume .........................................................................................................44
8. ADVERSE EVENT REPORTING......................................................................................45
8.1. Requirements...........................................................................................................45
CCI
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 58.1.1. Additi onal Details on Recording Adverse E vents on the CRF ................... 46
8.1.2. Eliciting Adverse Event Information ................................ .......................... 46
8.1.3. Withdrawal From the Study  Due to Adverse Events (see also the 
Subject Withdrawal section) ................................ ................................ ............ 47
8.1.4. Time Period for Collec ting AE/SAE Information ................................ ......47
8.1.4.1. Reporting SAEs to Pfizer Safety ................................ ............... 47
8.1.4.2. Recording Non -serious AEs and SAEs on the CRF ................. 47
8.1.5. Causality  Assessm ent .................................................................................47
8.1.6. Sponsor’s Reporting Requirements to Regulatory  Authorities .................. 48
8.2. Definitions................................ ................................ ................................ ............... 48
8.2.1. Adverse Events ................................ ................................ ........................... 48
8.2.2. Abnormal Test Findings ................................ ................................ ............. 49
8.2.3. Serious Adver se Events ................................ ................................ .............. 49
8.2.4. Hospitalization ................................ ................................ ............................ 50
8.3. Severity  Asse ssment................................................................................................51
8.4. Special Situations ................................ ................................ ................................ ....51
8.4.1. Potential Cases of Drug -Induced Liver Injury................................ ............ 51
8.4.2. Exposure to the I nvestigational Product During Pregnanc y or 
Breastfeeding, and Occupationa l Exposure ................................ ..................... 53
8.4.2.1. Exposure During Pregnancy ................................ ...................... 53
8.4.2.2. Exposure Duri ng Breastfeeding ................................ ................ 54
8.4.2.3. Occupational Exposure ................................ ............................. 55
8.4.3.Medication Errors and Lack of Efficacy ................................ .................... 55
8.4.3.1. Medica tion Errors ................................ ................................ ......55
8.4.3.2. Lack of Efficacy ................................ ................................ ........ 56
9. DATA ANALYSI S/STA TISTICAL  METHODS ................................ ............................... 56
9.1. Sample Size Determination ................................ ................................ ..................... 56
9.2. Efficacy Anal ysis................................ ................................ ................................ ....56
9.3. Pharmac okinetic Analy sis................................ ................................ ....................... 56
9.3.1. Plasma ................................ ................................ ................................ ......... 57
9.3.2. Urine ................................ ................................ ................................ ........... 58
9.4. Safet yAnal ysis................................ ................................ ................................ ........ 59
9.4.1. Electrocardiogram Analy sis................................ ................................ ........ 59
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 69.5. Data Monitoring Committee ................................ ................................ ................... 60
9.6. I nterim An alysis................................ ................................ ................................ ......60
10. QUALITY CONTROL  AND QUALITY ASSURANC E.................................................60
11. DATA HANDLING A ND RECORD KEEPING ................................ ............................. 60
11.1. Case Report Forms/Data Collection Tools/Electronic Data Record ..................... 60
11.2. Record Retention ................................ ................................ ................................ ...61
12. ETHI CS................................ ................................ ................................ .............................. 62
12.1. I nstitutional Review Board/Ethics Committee ................................ ...................... 62
12.2. Ethical Conduct of the Study ................................ ................................ ................ 62
12.3. Subject I nformation and Consent ................................ ................................ .......... 62
12.4. Reporting of Safet y Issues and Serious Breaches o f the Protocol or ICH 
GCP ................................ ................................ ................................ ........................... 63
13. DEFINITION OF EN D OF TRIAL ................................ ................................ ................... 63
13.1. End of Trial in the United States................................ ................................ ........... 63
14. SPONSOR DISCONTINUATION CRIT ERIA ................................ ................................ 64
15. PUBLICATION OF S TUDY RESUL TS................................ ................................ .......... 64
15.1. Comm unication of Resul ts by Pfizer ................................ ................................ ....64
15.2. Publications by  Investigators ................................ ................................ ................ 65
16. REFERENCES ................................ ................................ ................................ .................. 66
LIST OF TABLES
Table 1. Identity  of Investigational Product ................................ ................................ .......28
Table 2. Treatment Schema ................................ ................................ ................................ 29
Table 3. Safety  Labora tory Tests ................................ ................................ ........................ 40
APPENDICES
Appendix 1. Abbreviations ................................ ................................ ................................ ......67
Aztreonam-Avibactam 
C3601006Final Protocol Amendment 1, 14 July 2021
PFIZER CONFIDENTIAL
Page 7SCHEDULE OF ACTIVITIES
The schedule of activities table provides an overview of the protocol visits and procedures.  Refer to the STUDY PROCEDURES and 
ASSESSMENTS sections of the protocol for detailed information on each procedure and assessment required for compliance with the 
protocol. 
The investigator may schedule visits (unplanned visits) in add ition to those listed in the schedule of activities table, in orde r to conduct 
evaluations or assessments required to protect the well-being of the subject.
Visit Identifier ScreeningaDay -2 Day -1 Day 1 Day 2 Day 3 Day 4 Follow-upl
S1 S2
Hours post dose 0 0.5 6.5 8.5 0 3 4 6-8 12-16 24 EOT
Informed consent X
CRU confinement X
Inclusion/exclusion criteria X X
Medical history X X
Demography X
Physical examinationoXXmXi
Heightband weight X X
Review illegal drug/alcohol/tobacco use X X
Medication history X X
Safety laboratory X X X X X
Pregnancy test X X
Contraception check X X X
Serum FSHcX
Serologic tests: HIV, HBsAg, and 
HCVAb testingX
Urine drug testing X X
eGFR assessmentdXX X
Supine 12-lead ECG X XeXXeXX
Single supine blood pressure, pulse rate
and tem peratureXXeXfXe,fXe,fXfX
ATM-AVI loading dose (30 min 
infusion)kX
ATM-AVI extended loading dose (3 hour infusion)
kXk
ATM-AVI maintenance dose (3 hour infusion) q6hX→→ XCCI
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 8Visit Identifier ScreeningaDay -2Day -1 Day 1 Day 2 Day 3 Day 4 Follow -upl
S1 S2
Hours post dose 0 0.5 6.5 8.5 0 3 46-812-16 24 EOT
Cohort 1 –normal renal functio n
ATM -AVI maintenance dose (3 ho ur 
infusion) q8h
Cohort 2 –severe renal impairm entX  X
Urine sampling for ATM -AVI PKg,h(see 
PKsampling schema below)Xg  X
Blood s ampling for ATM -AVI PKp(see 
PK sampling schema below )X          X
Serious and non -serious a dverse event 
monitorin gX X X             X X
Prior/ Concomitant treatments X            X
Standardized mealsjX             X
Discharge from clinic X
Abbreviations: = ongoing/continuous event; ATM = aztreonam; AVI = avibactam; BSA = body su rface area; CRU = clinical research unit; 
ECG =electr ocardiogram; eGFR = estimated glomerular filtration rate; EOT = end of trial; FSH =follicle- stimulating hormone; HCVAb = hepatitis C core 
antibody ; HepBsAg = hepatitis B surfac eantigen; HIV = human im munodeficiency vir us; MDRD= Modif ication of Diet in Renal Disease; 
PK=pharmacokinetic(s); S = Screening Visit .
a.Subject w ill be screened w ithin 28 days prior to administration of the investigational product.
b.Height measurement o nly at Screening when ful l physical examinat ion is performed.
c.To be conducted f or females who have achieved postmenopausal status, defined as cessation of regular menses for at least 12 consecutive months with no 
alternative pathological or physiological ca use. 
d.To confirm eligibi lity, subjects mus thave stable renal function defined as 25% difference betw een 2 measurements of eGFR obtained, from the same 
laboratory, on 2 separate occasions during the Screening period that are at least 72 hours but no more than 14 days apart.  Additionally, differe nce be tween 
eGFR Screening 1 value and Day -2 value should be 25%.  The Day -2 eGFR values will be used for group placement.  The eGFR determination will 
utilize the MDRD formula adjusting f or BSA (See Section 3.1). 
e.Pre-dose.
f.Temperature does not need to be collected at this timepoint.
g.Instruct subject to void prior to administration of study treatment (p re-dose collection).  Instruct subject to void into the collection cont ainer at the end o f
each collection period.
h.Urine will be collected pre -dose on Day 3, and then during collection periods of 0- 2, 2-4, 4-6, and 6-8 (C ohort 2 only) hours after dosing.
i.Limited physical examination .
j.See Section 4.3.1 for more deta ils.
Aztreonam-Avibactam 
C3601006Final Protocol Amendment 1, 14 July 2021
PFIZER CONFIDENTIAL
Page 9Visit Identifier ScreeningaDay -2 Day -1 Day 1 Day 2 Day 3 Day 4 Follow-upl
S1 S2
Hours post dose 0 0.5 6.5 8.5 0 3 4 6-8 12-16 24 EOT
k. Loading dose and extended loading dose will be prepared in one infusion bag with an infusion rate change after the first 30 mi nutes.
l. A follow-up contact with each subject must occur at least 28 calendar days and up to 35 calendar days after the last administra tion of the investigational 
product to monitor for any AEs/SAEs and to verify contraception use. Contact with the subject may be done via a phone call.
m. Full physical examination, if deferred from the screening visit.
 
o. After the full complete physical examination (Screening or Day -2), further examinations will be performed at the discretion o f the investigator.
p. PK blood sample may be collected for the subjects who discontinue the study early for final safety assessments.C
C
I
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 10Pharmacokinetic Sampling Schema 
Visit Identifier 
Study Day 1 2 3 4
Hours Be fore/A fter Dose 0 0.5 3.5 6.5 8.5 0 2 3 3.25 3.5 3.75 4 5 6 8 12 16 24
ATM-AVI loading d ose
(30 m in infusion)iX
ATM-AVI extended loading dose
(3 hour infusion)iXi
ATM-AVI maintenance dose
(3 hour infusion) q6h
Cohort 1 –normal renal functionX   X
ATM-AVI maintenance dose
(3hour infusion) q8h
Cohort 2 –severe ren al imp airmentX  X
Blood sampling for ATM -AVI PKkXaXbXcXaX XjX X X X X X X X X X
Capillary sampling for ATM -AVI PKl
Cohort 1 –normal renal functionX X X X X X X
Trough blood sampling for ATM -AVI 
PK
Cohort 1 –normal renal functionXd  Xe
Trough blood sampling for ATM -AVI 
PK
Cohort 2 –severe renal impairmentXd Xe
Urine sampling for ATM -AVI PKf,h
Cohort 1 –normal renal functionXf       X
Urine sampling for ATM -AVI PKg,h
Cohort 2 –severe renal impairmentXg        X
Abbrev iation s: ATM = aztreonam; AVI = avibactam; IV = intravenous ;PK = pharmacokinetic .
a.Predose sample collection .
b.Collect PK bloo d sample within 5 min before the end of the loading dos eIV infusion .
c.Collect PK blood sample within 15 min before the e nd ofexten ded load ngIV infusion .
d.Collect maintenance pre- dose PK blo od sample within 10 min before start of each maintenance dose infu sion.
e. Trough sample does not need to be collected for f inal maintenance dose on Day 3 as pre- dose sample wi ll already be collected as part of intensive PK 
sampling collection .
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 11Visit Identifier 
Study Day 1 2 3 4
Hours Be fore/A fter Dose 0 0.5 3.5 6.5 8.5 0 2 3 3.25 3.5 3.75 4 5 6 8 12 16 24
f.Urine will be collected pre dose on Day 3, and then during collection periods of 0-2, 2-4, and 4-6hours after dosing.
g.Urine will be co llected pre dose on Day 3, and then during collection periods of 0- 2,2-4, 4-6, and 6 -8hours after dosing.
h.Instruct subject to void pr ior to administration of study treatment (pre -dose collection).  I nstruct subject to void into the collection container a tthe end of 
each collection period.
i.Loading dose and extended lo adingdose will be prepared in one infusion bag with an infusion rate change after the first 30 minutes .
j.Collect PK blood sample within 15min before IV infusion stop .
k.PK blood sample may be collected for the subjects who discontinue the study early for fi nal sa fety assessments .
l.Collect finger -prick capillary PK blood sample time-matched to venous PKblood sample forsubjects in Cohort 1 –normal renal function .
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 121.INTRODUCTION
1.1.Mechanism of Ac tion/Indication
Aztreonam -avibactam (ATM -AVI) is a combination prod uct that co ntains the -lactam 
antibiotic aztreonam (ATM) and the non --lactam -lactamase inhibitor av ibactam (AVI).  
ATM -AVI is being developed to treat infections caused by  resistant Gra m-negative 
pathogens, including those with metallo- lactamase (MBL )-mediated drug resistance.
1.2.Background 
The prevalence of multi- drug r esistant (MDR) bacteria is increas ing worldwide.  This has 
become a significant public health threat as there are fewer, or even sometimes no, effective 
antimicrobial agents available fo r infections cau sed by  MDR bacteria.1,2  In particular, 
ongoing surveillance studies have demonstra ted an increasing frequency  of antibiotic 
resistance among MDR Gram- nega tive bacter ia.  New antibiotics or combinations of existing 
antibi otics with resistance enzyme inh ibitors are urgently  needed to provide treatment 
options for patients with infections k nown or suspected to be caused b y MDR Gram -negative 
pathogens .3,4
Aztreonam is an established injectable antibiotic indicated for the treatment of various 
infections caused b y susc eptible Gram -negative bacteria.  It has a unique monocy clic 
-lacta m nuc leus that m akes it structurally  different from other -lactam ant ibiotics, as well 
as several chem ical side groups that interfere with degradation by  MBLs.  In this way , 
activity  again st MBL (Class B) producing pathogens is possible, although potentia l 
inactivation b y Class A, C, or D -lactamases remains problematic.
Avibactam is a novel, non -lactam ,-lactamase inhibitor of a broad spectrum of enzy mes, 
including Ambler Class A extended -spectrum  -lactamases (ESBLs), Class A Klebsiella
pneumoniae carbape nemase (KPC), and Class C (AmpC) enzy mes, and some Class D 
enzy mes.  Its beneficial effect in comb ination with aztreonam occurs by inhibiting the 
enzy mes that inactivate aztreonam.
Together, aztreonam and avibactam have the potential to address the un met n eed fo r safe and 
effective agents to combat MBLs and other problem atic -lactamases, such as ESBLs and 
KPCs, which m ay be co -expressed with MBLs and contribute to MDR.
Aztreonam has be en marketed a s a stand -alone product under the tradename AZACTAM
for ov er 25yearswhile avibactam was approved in 2015 (US)/2016 (EU) aspart of a 
combination product w ith ceftazdime ( AVYCAZ/ZAVICEFTA).
The serum half -life of aztreonam averaged 1.7 hours (1.5 to 2.0 hours) in subjects with 
normal renal function, indep enden tof the do se.  In healthy  subjects, based on a 70 kg person, 
theserum clearance (CL) was 91 mL/min and renal clearance (CL r)was 56 mL/min; the 
apparent mean volume of distribution a tsteady -state (Vss)averaged 12.6 L, approximately  
equivalent to e xtrac ellular fluid volume.   Intravenous ( IV) administration of a single 500 mg 
or 1000 m g dose of aztre onam q8h for 7 days to healthy  subjects produced no apparent 
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 13accumulation of aztreonam or modification of its disposition characteristics; serum protein 
bindi ng ave raged 56% and was independent of dose.5
Avibact am demonstrated approximately  linear pharmacokinetics ( PK)across the dose range 
studi ed for single IV administration with a 30 -min infusion time (50 to 2000 m g avi bacta m 
alone) and time -invariant PK across the dose range s tudied for multiple IV doses with a 
30 min infusion time (500 to 1000 mg avibactam).  Following IV administration, the 
maximum observed concentration ( Cmax)of avibactam is achieved at t he en dof infusi on, 
after which plasma concentrations decline in a mul ti-exponential manner.  The half -life of 
avibactam ranged from 1.4 to 3 hours and resulted in little or no accumulation upon repeated 
administration.
The carbon -14 [14C]avibactam absorp tion, distribution, metabolism, and excretion (ADME) 
study  showed that an average of 97% (range, 95% to 98%) of administered radioactivity  was 
recovered from the urine, over 95% within 12 hours of dosing.  Avibactam is predominantly  
renall y cleared and met aboli sm has little contribution to its excretion.  An average of 
85% (r ange, 67% to 101%) of administer ed avibactam was recovered from the urine during 
the study , with >50% being recovered w ithin 2 hours of the start of the infusion.  CL rwas 
158mL/min su ggest ing ac tive tubular secretion. 
The PK of avibactam (100 mg, singl e 50-mL IV infusion over 30 minut es) in renall y 
impaired patients was assessed in the ceftazidime- avibactam (CAZ -AVI) program . 
Avibactam exposure, expressed b y area under the curve ( AUC 0-),incre ased with increasing 
level of renal impairment by  approxima tely 2.7-, 3.9-, 7.7- , and 21.3-fold for patients with 
mild, moderate, severe renal impairment, and end -stage renal dise ase (ESRD) , respectivel y.  
This was associated with a decrease in aviba ctam c leara nce with increasing severit y of renal 
impairment, which is consistent with CL rbeing th e dominant elimination route.  The 
relationship between avibactam renal clearance and c alculated creatinine clearance (CrCL ) 
was found to be linear.  The impa ct on clear ance resulted in the increasing half-lifefrom less 
than 2 hours in subjects with normal renal function up to about 8 hours for patients with 
severe renal disease and 22 hours in patients with end-stage renal failure.  Mean C maxalso 
increa sed w ith the deg ree of renal impairment.  The inter -individual variabi lity (expressed b y 
the coefficien tof variation [CV%]) of C maxand area under the curve at steady -state (AUC ss)
was als omarkedly  higher in patients with renal impairment than in healthy subj ects. Time to 
reach Cmax(Tmax)remained consistent at the end o f infusion at 30 minutes, and V ssalso 
remained roughl y comparable across the groups.
The PK of aztreonam has been stud ied in patients with renal impairment where all subjects 
received a single 1000 mg aztreonam IV bolus dose or as a 2- min IV infusion, wit hfrequent 
blood sampling for at least 24 h post -dose for drug concentration and PK analy sis.6,7  Both
studies included a healthy control group (n=6 per study ) with creatine clearance ( CrCL )
80mL/min.
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 14One study6included patients with v arious degrees of chronic renal f ailure (n=12; mean SD 
CrCL  17.8  13.5mL/min; range 4.8-49.9 mL/min). In this study  the half -life (mean  SD) 
was significantly  increased (p<0.001) from 1.8 0.14 hours in subjects with normal renal 
function to 4.9 1.06 hou rs in patients with chronic renal failure.   The corresponding 
statistica lly signifi cant decreases (p<0 .001) in aztreonam CL  were 84.2 7.8mL/h/kg in 
subjects with normal renal function to 30.2  9.2mL/h/kg in patients with chronic renal 
failure.
The other study7included 4groups ( n=6/gr oup) with CrCL  of >80, mL/min, 30-79mL/min, 
10-29mL/min, and <10 mL/min, respectively . Thehalf-life (mean SD) increased 
(p<0.001) with decreasing renal function, from 1.98 0.12 h (normal renal function), to 
3.420.80 h, 4.76  0.85 h, and 6.02  1.53 h, respectivel y. Aztreonam CL decreased from 
107mL/min in subjects with normal renal funct ion to 29 mL/min for functionally  anephric 
patients. Urinary  excretion (urine collect ed in intervals up to 48 hours post dose) of 
aztreonam was also det ermin ed in this study . Urinary  recovery  of aztreonam ranged from 
58% of the administered dose in normal subje cts to 1.4% in uremic patients.
Both avibactam and aztreonam were shown to be a substrates of the human organic anion 
transporter (OAT) proteins O AT1 a nd OAT3.
Invarious Phase 1/2a studies, it has been shown that t here are no PK interactions betwee n
ceftazdime (CAZ )and AVI, CAZ -AVI and metronidazole, ceftaroline and avibactam, or 
aztreonam and avibactam, which validates the use of data from these indiv idual components 
to support the ATM -AVI program .
At steady  state (Day 10 of dosing q6h) statistical comparison (anal ysis of variance 
[ANOVA]) showed a difference in PK of avibactam when it was co- administered with 
aztreonam in elderl y versus y oung subjects (aztreonam AUC ssincreased b y 22.6%; C ss,max
increased b y 15.8% and C ss,min was increased b y 54.4 %in elderl y subjects).  Corresponding 
changes were observed for avibactam where AUC ssincreased b y 32.7%; C ss,max increased 
31.1% and C ss,min was increa sed b y 74.2 % in elde rly compared to y oung subjects.  Post -hoc 
modellin gsuggested this may  be related t odifference in renal function in these patients.
Additional information for this comp ound may  be found in the single reference safet y 
document (SRSD) , which for this st udy is the ATM -AVI I nvestigator’s Brochure (IB).
A dual- analyte bioanal ytical assay  hasbeen developed a nd valid ated for simultaneous 
analysis of a ztreo nam and avi bactam pla sma concentrations from a single microvol ume 
plasma sample (min imum 5 µL of plasma) tosupport planned pediatric clinical t rials in the 
ATM- AVI development program .  This assay  enable s collection of much lower blood sample 
volume sfor evaluation of PK in children, including a blood microsample (≤50 µL)that may  
be collect ed viacapillary sampling .  
Aztreonam-Avibactam 
C3601006Final Protocol Amendment 1, 14 July 2021
PFIZER CONFIDENTIAL
Page 151.3. Rationale 
1.3.1. Study Rationale Dose adjustment for aztreonam and avibactam are warranted in renal impairment given that 
both are eliminated primarily as unchanged substances  by the kidney.  This study is therefore 
being conducted to evaluate the effect of seve re renal impairment on the PK, safety and 
tolerability of ATM-AVI.  Results from this study along with previous renal impairment PK data from each of the ATM-AVI components will be used to confirm proposed ATM-AVI dosing in severe renal impairment which was based on modelling/simulation.
Capillary blood microsamples will be collected from subjects in Cohort 1 (normal renal 
function) at specified time points matched to standard venous blood sample collection to evaluate the correlation/concordance of plasma concentrations for aztreonam and avibactam from microsampled capillary and venous blood collections. Results from this sub-study will be used to confirm the microsampling technique prior to inclusion in pediatric protocols.
 
 
 
 
 
 
 
 
 
 
 
 
1.3.2. Dose Rationale
The intention for ATM-AVI is that it will be active against clinically isolated Gram-negative 
bacteria for which there are limited or no treatment options when dosed in a fixed 3:1 ratio.  The ATM-AVI doses for this Phase 1 study (and proposed for Phase 3) have been selected based on pre-clinical and clinical data on ATM-AVI, using PK data for ATM, AVI and 
ATM-AVI and including covariate information collected in healthy volunteers and patients 
to construct a robust population PK model.  Furthermore, AVI PK and safety data together with PK/pharmacodynamic (PD) modelling results obtained during development of the new 
CAZ-AVI combination product Avycaz
™in the US (Zavicefta®in Europe) have been taken 
into account.8,9
Dose selection (ATM-AVI) for patients with normal renal function
In this Phase 1 study, the dosing regimen is the same as that administered in Cohorts 2 and 3
of the Phase 2a study and what is being evaluated in Phase 3.  The loading dose for patients with normal renal function or mild renal impairment (CrCL or GFR >50 mL/min) is 500 mg CCI
CCI
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 16ATM plus 167 mg AV I infused over a 30 minute period, immediately  followed by  an 
extend edloading dos e of 1500 mg ATM plus 500 mgAVI over a thre e hour period.  
Three (3) hours after the extended l oading dose is completed, a maintenance dose of 1500 mg 
ATM and 500 mg AVI is infused over 3 hours and administered every  6hours (q6h).  The 
targeted total daily dose on Day 1is 6500 mg ATM/21 67mg AVI.   From Day 2onwards, the 
maximum daily  dose will be 6000 mg ATM/2000 mg AV I. 
For patients with serious bacterial infections where there are limited or no treatment options, 
it is recommended for -lactams to ra pidly achieve target at tainme nt and steady  state 
concentration s while prolonging time above the minimum inhibitor y conc entration (MI C) 
with extended infusion time and shorter dosing intervals.  The rationale for the sel ected dose 
regimen is based on the ob jective of obtaining op timal exposure to achieve a 
>90% probab ility of target attainment (PTA) against PK/PD targ ets fo r both ATM and AVI 
which have been identified from non -clinical data.   The PK/PD targets are:
Mainta in unbound ATM concentration s above a n MI Cfor 60% of the do sing interval;
Maintain unbound AVI con centrations above a threshold concentration (C T) of
2.5 m g/L for 50% of the dosing interval .
The dose has been selected to achieve >90% PTA at an ATM -AVI MICof 8mg/L.
Population PK mo dels have been constructed using the following data: ATM PK data from 
the literature ,ATM and AVI PK data from the Phase 1study (C3601005 ) ofthe ATM -AVI 
development program ,and AVI PK data from the Zavicefta development progr am (AVI in 
combination with CAZ) whic h included a substantia lamount of PK data in patients.  Most 
recentl y, the PK model was updated using PK and cov ariate data from patients with 
complicated intra -abdominal infections (cIAI)in the Phase 2a stud y.  The P K models were 
used in Monte Carlo sim ulations of 5000 patient s to select a dosing regimen which ach ieved 
a >90% joint PTA for ATM and AVI based on PK/ PD tar gets:
In Cohort 1of the Phase 2a study  in patients with cIAI (and CrCL >50 mL/min) the dosing 
regim en was selected based on the Phase 1 safet y data and PK/PD m odeling above, ie, a 
loading dose (500 mg ATM plus 137 mg AVI b y IVinfusion) over a 30 minute period, was 
immediately  followed b y a maintenance infusion of 1500 mg ATM plus 410 mg AV I over a 
3 hour period [q6h]). 
The safet y and PK data from 10 patients in Coho rt1(who completed all safety  and PK 
assessments) was reviewed by a Scientific Advi sory Committee (SAC).  Based on 
assessment of the safet y and PK data in Cohort 1, Cohort 2 was subsequentl y initiated using 
a higher A VI dose ( a loading dose of 500 mgATM plus 167 mg AVI b y IV infusion ov er a 
30minute period, immediately  followed by  a do se of 1500 mg ATM plus 500 mg AV I by 
IVinfusion over a 3 hour period q6h [maintenance infusion]).   Follow ing the review of PK 
and saf etydata from 10 patients in Coh ort2by the SAC, the higher AVI dose w as continued 
in Cohort 3. The higher AVI dose was select ed as it provides a higher PTA for AVI using 
the PK/PD targets as described above compared to the lo wer AVI dose. 
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 17Dose selection (ATM- AVI) for patients with se vere renal impairment ( GFR >15to 
30 m L/min)
In this Phase 1study , the dose for patients with severe renal impairment ( GFR >15 to 
30mL/min) is a loading dose of 675 mg ATM plus 225 mg AVI b y IV infusion over a 
30minute period, i mmediately  followed by  an extended loading dose of 675 mg ATM plus 
225mg AV I by IV infusion over a 3 hour period, then following a 5hour gap, maintenance 
dose of 675 mg ATM plus 225 mg AVI b y IV infusion over 3 hours q8h.
Doses for patients wit h impaire d renal function are ba sed on PK modeling and simulation .  
Thepopulation PK models for both ATM and AVI included data from patients with renal 
impairment which allowed the use of modeling and simulation for dose select ion in Phase 2a 
and3.  The dose sele ction for patients with sever e renal impairment was based on the 
following criteria: matching the predicted ATM s teady state area under the curve between 
time 0and 24 hours after dose (AUC (0-24,ss)) in patients with severe renal impairment, to th e 
predict ed AUC (0-24,ss)in pati ents w ith normal renal function (CrCL  >80mL/min) receiving 
ATM 1500 mg/AVI 500 mg; mainta ining the same 3:1dosing ratio between ATM and AVI; 
and maintaining >90% joint PTA.  Furthermore, since t he dosing ratio between ATM and 
AVI i s fixed, and given the d ifferential impact of renal impairment on the clearance of ATM 
and AVI, it was accepted t hat matching an area under the plasma concentration versus time 
curve (AUC) target for ATM would result in exceeding the exposure targ ets for A VI in 
patients with nor mal renal function, but should not appr eciably  exceed the exposure in 
patients with mild r enal i mpairment with the standard dose. 
2. STUDY OBJECTIVES AND ENDPOINTS
Primary Objective (s): Primary End point (s): 
To evaluate the pharmacok inetics of the 
co-admin istration of aztreonam and avibactam 
following multiple doses via IV infusion in subjects 
with s evere renal impairment and in healthy subjects 
with normal renal function . Total daily a rea under t he plasma concentration time
profile from time 0 to 24 hours at steady -state
(AUC 0-24,ss)and C max.
Secondary Endpoint(s):
Area under the plasma c oncent ration -time profile 
from time 0 to to the time of the end of the dosing 
interval ( ) (AUC 0-), Tmax,observed concentration at 
the end of the dosing interval ( ) (C ), terminal 
elimination half -life (t½), clearance (CL), renal 
clearance (CL r), appare nt vol ume of distribution 
during terminal phase (V z), apparent volume of 
distribution at steady -state (V ss), amount of unchanged 
drug excreted into urine over dosing interv al(Ae 0-), 
Ae0-expressed as pe rcent of dose (Ae 0-%).
Secondary Objective (s): Seconda ry Endpoint(s): 
To evaluate the safety and tolerability of multiple doses 
of aztreonam and avibact amin subjects with severe 
renal impa irment and in healthy s ubject s with normal 
renal function .Safety will be assessed by physical examinations, 
adve rse ev ent (AE)monitoring, 12 -lead 
electrocardiograms (ECGs) , supine blood pressure and 
pulse rate, and cl inical laboratory tests .
Tertiary/Ex ploratory Objective(s): Tert iary/Exploratory Endpoint(s): 
Aztreonam-Avibactam 
C3601006Final Protocol Amendment 1, 14 July 2021
PFIZER CONFIDENTIAL
Page 18 
 
•To determine concordance/comparability of capillary
microsample plasma concentrations with venous plasmaconcentrations for aztreonam and avibactam in healthy subjects with normal renal function. 
 
•Comparison of concentrations (capillary 
microsamples collected at specified time points matched to venous plasma concentrations) assessed by
X-Y and Bland-Altman (B-A) scatter plots with limits 
of agreement (LoA) for a precision assessment.
3. STUDY DESIGN
3.1. Study OverviewThis is a Phase 1, open-label, parallel-group study where an IV loading dose (30 min 
infusion) followed by multiple IV doses (3 hr infusion) of ATM-AVI will be administered to subjects with severe renal impairment (not on dialysis) and to healthy subjects with normal renal function.  Subjects with the following levels of renal function will be enrolled:
Cohort Renal Impairment Number of Subjects eGFR
a(mL/min)
1 None (Normal) 6 ≥80
2 Severe (Not on dialysis) 5-6 >15 -≤30
Abbreviations: BSA = body s urface area; eGFR = estimated glomerular filtration rate; 
MDRD = Modification of Diet in Renal Disease.
a. Estimate of eGFR based on the MDRD formula adjusting for BSA.  The Day -2 eGFR values will be 
used for group placement.
•Step 1: eGFR (mL/min/1.73 m2) = 175 × (S cr, std)-1.154× (Age)-0.203 × (0.742 if female) × (1.212 if 
African American) where S cr, stddenotes serum creatinine measured with a standardized assay.
•Step 2: Convert the MDRD-derived, BSA-adjusted eGFR obtained above to absolute eGFR 
(mL/min) for eligibility assessment using the following equation: 
•eGFR (mL/min) = eGFR (mL/min/1.73 m2) × subject’s BSA where BSA is calculated as 
BSA = (Weight0.425 × Height0.725) × 0.007184.
Approximately 6 subjects will be enrolled into Cohorts 1 and 2.  Due to the potential
difficulty in recruiting subjects with eGFR ≤30 mL/min, the number of subjects to be 
enrolled in this group will be approximately 5-6 in order to have at least 5 evaluable subjects. 
The following equation from the MDRD study will be used to calculate eGFR (S cr, std denotes 
serum creatinine measured with a standardized assay for serum creatinine):
eGFR (mL/min/1.73 m2) = 175 × (S cr, std)-1.154 × (Age)-0.203 × (0.742 if female) × (1.212 if 
African-American)
Note that the value of eGFR, which is directly obtained from the lab or calculated using the
equation above, is generally normalized to an average body size of 1.73 m2for diagnosis, 
prognosis and treatment of renal disease. In terms of clearance of renally filtrated drugs (including secreted drugs), renal elimination capa city is r elated to absolute glomerular 
filtration rate (GFR) in mL/min. To use the MDRD-derived, body surface area(BSA)-adjusted value of eGFR to obtain absolute GFR (mL/min) for renal disease C
CICCI
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 19classification/cohort assignment , this va lue should be multip lied by  the individual subject’s 
BSA (ie,measured BSA/1.73 m2).The BSA of an individual can be cal culated by  the
following formula as described below:
1.BSA = (Weight0.425×Height0.725) × 0.007184
In summary , GFR in mL/min calculated as below will be use d for group placement: 
Step 1: Obtain the MDRD -derived eGFR:
eGFR (mL/min/1.73 m2) = 175 × (Scr, std)-1.154 × (Ag e)-0.203 × (0.742 if female) × 
(1.212 if African -American) where S cr, std denotes serum creatinine measured with 
a standar dized assay
Step 2: Convert the MDRD -derived, BSA -adjus ted eGF R obtained above to absolute 
GFR (mL/min) for eli gibility  assessment using the following equation: 
eGFR (mL/min) = eGFR (mL /min/1.73 m2) ×subject’s BSA where BSA is 
calculated as BSA = (Weight0.425×Height0.725) × 0.007184
CrCL will also be estima ted fro m a spot serum creati nine measurement using the f ollowing 
Cockcroft -Gaul t(C-G) equation:
2.CrCL(mL/min) = [140 –age (y ears)] × total body weight (kg) × (0.85 for females)
72 × serum creatin ine (mg/dL)
Note tha t eGFR calculated by  the MDRD equat ion will be used f or group p lacement .  
Nevertheless, ren al functio n will be est imated using both C -G and MDRD equations in this 
study .
All subjects must have stable renal function to enter the study . Stable renal function is 
defined as  25% difference be tween 2 measurements of eGFR obtained, from the same 
laboratory , on 2 separate occasi ons during the screening period that are at least 72 hours but 
no more than 14 days apart. Additionally , difference between eGFR Screening 1 value and 
Day -2 value should be 25%.The Day  -2eGFR value wil l be used for group placement.  
The CrCL value wi ll be recorded at the same time eGFR is determined.
All screening evaluations will occur within 28 days prior to adm inistration of the 
investigational product.  All subjec ts will provide informed con sent and undergo screening 
evaluations to determine their eligibility .  Eligible subjects will check into the Clinical 
Research Unit (CRU) onDay -2.  S ubjects will receive a loading /extended l oading dose 
followed b y multiple doses of IVATM -AVI according to Table2(seeSection 5.4). 
Serial blood samples and urine at spec ified intervals will be collected pre -dose and for 
24 hours following the fi nal maintenance dose administered o n the morning of Day 3 for PK
assessments . PK samples will also be collected 0.5 and 3.5 hours after start of loading dose 
on Day 1 as well as trough samples collec ted just prior to administration of mainte nance 
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 20doses over the course of the study . Subjec tsfrom Cohort 2 (sever erenal impairment) will be 
recruited first.  The healthy  subjects will then be recruited . An attempt will be made to 
choosesuch that each subject’s age is within 10years and weigh t is within 15kg of the 
mean demographics for t he severe renal impairme nt cohort , and maintain a similar 
male/female ratio ( 2 subjects per gender). 
The total participation time for each subj ect in this study  will be approximately  6days 
(excludi ng Scre ening).
4.SUBJEC T ELIGIBILITY CRITERIA
This study  can fulfill its objectiv es onl y if appropriate subjects are enrolled.  The following 
eligibility  criteria are designed to select subjects for whom participation in the study  is 
considered appropriate. All re levant medical and nonmedical conditions should be t aken into 
considerat ion when deciding whether a particular subject is suitable for this protocol.
4.1. Inclusion Criteria
Subjects must meet all of the following inclu sion criteria to be eligible for enrollmen t in the 
study :
1. Female subjects and/or male subje ctswho, at the time of Screening, are between the 
ages of 18 and 75years, inclusive.
Male and female subjects of childbearing potential must agree to use highl y 
effective method(s) of contraception ( refer to Section 4.3.4 ).  A subject is of 
childbearing potential if, in the opinion of the investigator, he/she is biologically  
capable of having children a nd is sexually  active.
Female subje cts of nonchildbearing potential must meet at least 1 of the following 
criteria :
a.Achi eved postmenopausal status, defined as follows : cessation of regular 
menses for at least 12 consecutive months with no alternative patho logical or 
physiological cause; and have aserum follicle- stimulating hormone (FSH)
level conf irming the postmenop ausal state ;
b.Have undergone a documented hy sterectom y and/or bilateral oophorectomy ;
c.Have medically  confirmed ovarian fai lure.
All other fema le subjects (including female subje cts wit h tubal ligati ons) are
considered to be of childb earing potential.
2.Body mass index (BMI ) of 17.5 to 40.5kg/m2; and a total body weight >50 kg 
(110 lb).
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 213.Stable renal function defined as 25% difference between 2 measurements of eGFR
obtained, from the sam e laboratory , on 2 separate occasions during the s creening 
period that a re at least 72 hours but no more than 14 days apart.  Additionally , 
difference between eGFR Screening 1 value and Day  -2 value should be 25%.  The 
Day -2eGFR value will be use d for group placement .
4.Evidence of a personally  signed a nd dated informed conse nt doc ument indicating that 
the subject has been informed of all pertinent aspects of the study . 
5.Subjects who are willing and able to compl y with all scheduled visits, treatment plan,
laboratory  tests, and other study  procedures.
4.1.1. Speci fic Requirements for Healt hy Subjects with Normal Renal Function
1.Health y asdefined as no clinically  relevant abnormalities identified by  a de tailed 
medical histo ry, full phy sical examination, incl uding b lood pressure (BP) and pulse 
rate (PR) measurement, 12-lead ECG , or clin ical laboratory  tests.
2.Normal renal function ( eGFR 80mL/min) at Screening based on the Day  -2value ,
using the MDRD form ulaadjusting for BS A (See Section 3.1). 
3.An at tempt will be made to e nrolldemographically comparable to the group of 
subjects with severe impaired renal function.
Body weight within 15kg of the mean body  weig ht of the group of subjects with 
severe renal impairment .
Age within  10years of the mean ageof the group of subj ects with severe renal 
impairment.
Gender ratio for the group similar ( 2subjects per gender) to the group of 
subjects w ithsevere renal imp airment.
4.1.2. Specific Requirements for Subject s with Severe Renal Impairment
1.Good general healt h commensurate with the popul ation with chronic kidney  disease 
(renal impairment).
2.Documented severe renal impairment indicated b y aeGFR >15 -30mL/min but not 
requiring hemodial ysis, based on the Day  -2value ,using t he MDRD formula
adjusting for BSA ( SeeSection 3.1).
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 224.2. Exclusion Criteria
Subjects with any  of the following character istics/conditions will not be included in the 
study :
Exclusion Criteria : All Subjects
1.A positive urine drug test.
2.Urinary  incontinence witho ut catheterization. 
3.History  of regular alcohol consumption exceeding 7 drinks/week for female subject s 
or 14drinks /week for male subje cts(1drink = 5ounces [150 mL] ofwine o r 
12ounces [360 mL]of beer or 1.5 ounces [45 mL] o f hard liquor) within 6 months 
before Screening .
4.Treatment with an investigational product within 30 days (or as determined by  the 
local requi rement) or 5half-lives preceding the first dose of inv estigat ional produc t
(whichever is longer ).
5.Subjects wi th ANYof the following abnorm alities in clinical laboratory  tests at 
Screening, as assessed b y the study -specific laboratory  and confirmed b y a single 
repeat test, if deemed necessary :
Aspartate aminotransfe rase(AST )oralanine aminotransferase (ALT) level
>1.0 × upper limit of norma l (ULN );
Total bilirubin level >1.0 × ULN; subjects with a history  of Gilbert's s yndrome 
may have direct bilirubin m easured if total bil irubin level >1.0 × ULN and would 
be eligi ble for this study  provided the direct bilirubin level is ULN;
Activa ted partial thromboplastin time ( aPTT) , prothrombin time (PT) and/or 
international normalized ratio (INR) >1.0 ×ULN .
6.Pregnant female subject s; breastfeeding female subject s; fertile m ale subjects and 
female subjects of childbearing potential who are unwil ling o r unable to use a highly  
effective method of contraception as outlined in this protocol ( Section 4.3.4 )forthe 
duration of th e study and for at least 28daysafter the last dose of inve stigational 
product .
7.Use of prescription or nonprescription drugs and dietary supplements within 7 days or 
5half-lives (w hichever is longer) prior to the first dose of investigational product .  As 
an exception, acetaminophen /parace tamol may be used at dos es of  1g/day.  Limited 
use of nonprescription medications that are not believed to affect subject safety  or the 
overall results of the study may be permitted on a case-by-case basis following 
approval b y the sponsor . 
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 23For subjects with severe renal impai rment ,concomitant medications may  be given if 
they are considered necessary  for the welfare of study  subjects ( eg,standard therap y 
for under lying diseases), are not contraindi cated w ith the stud y drug, and are unlikely  
to interfer e with the PK/PD response of the stud y drug. Subjects must be receiving 
stable doses of these concomitant medicatio ns for at least 28 days before S creening . 
If conc omitant medications are likel y to i nterfer e with the P K/PD response of the 
study  drug, the y ma y be substituted wit hagents that have similar pharmacological 
effects. 
Use of o ral anticoagulants and potent inhibitors of OAT 1 and/or OAT3 
(eg,probenecid) are prohibited in this study for all subjects.
8.Blood dona tion (excluding plasma donations) of approximately  1pint (500 mL)or 
more within 60 days prior to dosing .
9.History  of sensitivity  to heparin or heparin -induced thrombocy topenia .
10. His tory of serious alle rgy, hy persensitivity  (eg,anaphy laxis), o r any  seriou s reaction 
to aztreonam, carbapenem, monobactam or other -lactam antibiotics, avibactam, or 
any of the excipients of the respective (investigational) medicinal products to be 
admini stered during the st udy.
11.History  of human immunodeficie ncy virus (HIV), hepatitis B,or hepatitis C; positive 
testing for HIV, hepatit isB surface antigen (HepBsAg), or hepatitis C antibody  
(HCVAb) .
12.Unwilling or unable to comply  with the criteria in the Lifestyle Require ments section 
of this protocol.
13.Subjects who are inve stigat orsite staff memb ers directly  involved in the conduct of 
the study and their family  members, site staff members otherwise supervised by  the
investigator , or subjects who are Pfizer employ ees,including their family  members,
directl y involved in the conduct of the study .
14. Ot her a cute or chronic medical or ps ychiatric condition including recent (within the 
past y ear) or activ e suicidal ideation or behavior or laboratory  abnormality  that may  
increase the r isk associated with study part icipation or inves tigational product 
admini stration or may  interfere with the interpretation of study  results and, in the 
judgment of the investigator, would make t he subject inappropr iate for entry  into this 
study .
15.Subject ha s past or current history  of epileps y or seizure disorders excluding feb rile 
seizures of childhood.
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 24Exclusion Criteria : Subjects with Severe Renal Impairment
1.Subjects with any  significant hepati c, cardiac, or pulmo nary disease .
2.Renal allograft recipients or subjects who are clinically nephrotic.
3.Scree ning supine 12- lead ECG d emonst rating QT interval corrected b y Frideric ia’s 
formula ( QTcF )>470 msec or a QRS interval >120 msec.  If initial QTcF exceeds 
470msec, or QRS exceeds 120 msec, the ECG shou ld be r epeated 2 more times and 
the a verage of the 3 QTcF or QRS values should be use d to determine the subject’s 
eligibility .
4.Screening supine BP180millimeters of mercury  (mm Hg) (s ystolic) or 
110mmHg (diastolic), on a single measurement (confirmed by a single repeat, if 
necessary ) following at least 5 minutes of rest.   If BP is 180mm Hg (s ystolic) or 
110mm Hg (diastolic), the BP should be repeated 2 more times and the average of 
the 3 BP val ues should be used t o determine the subject’s elig ibility .
5.Subjects requiring dialy sis.
Excl usion Criteria : Healthy Subjects with Norm al Ren al Function
1.Evidence or history  of clinically  significant hematological, renal, endocrine, 
pulmonary , gastrointestin al, cardiovascular, hepatic, psy chiatric, neurolog ic, or 
allergic disease (including clinica lly relevant and significant drug allergie s, but
excluding untreated, as ymptomatic, seasonal allergies at time of dosing).
2.Screening supine 12- lead ECG demonstrating QTc F>450msec or a QRS interval
>120 msec.  If initial QTc Fexceeds 450 msec, or QRS exce eds 120 msec, the ECG 
should be repeated 2more times and the average of the 3QTcFor QRS values should 
be used to determine the subject’s eligibility .
3.Screening s upine BP  140mm Hg (systolic) or 90mm Hg (diast olic), follo wing at 
least 5 minutes of supine rest.  If BP is 140mm Hg (sy stolic) or 90mm Hg 
(diastolic), the BP should be repeated 2 more times and the average of the 3 BP 
values should be used to determine the subject’s eligibility .
4.3.Lifestyle Require ments
The f ollowing guidelines are provid ed:
4.3.1. Meals and Die tary Restrictions
Subject smust abstain from all food and drink (except water) at least 4 hours prior to 
any safety laboratory  evaluations and at l east 1hour prior to ECG evaluations.
Breakfast will be provid ed approximately  1hour after dosing on Day 1 (loading 
dose) .On Day 3, breakfast will be provided prior to administration of the final 
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 25maintenance dos e but after the pre -dose safety laboratory tests, ECG, BP and PR
procedures have been comple ted. Breakf astcan be given at an y time o n all other 
days.
Lunch will be provided a pproximately  4-5hours after dosing on Day 1 (loading dose) 
and Day 3 (final dose) .Lunch can be given at any time on all other day s.
Dinner will be provided approximately 9to10 hou rs after dosing on Day 1 (load ing 
dose) and Day 3 (final dose) .Dinner can be given at an y time on all other days.
An evening snack may be permitted .
The continuation of a renal diet is permitt ed.
Subjects will not be allowed to eat or drink g rapef ruit or grapefruit -related citrus 
fruits (eg, Seville oranges, pomelos) from 7 days prior to the first dose of 
investigational product until collection of the final PKblood sample .
While confined, the total daily  nutriti onal composition should be app roximately 
55%carboh ydrate, 3 0%fat,and 15% protein.  The daily  caloric intake per subje ct 
should not exceed approximately  3200 kcal.
4.3.2. Alcohol, Caffeine ,and Tobacco
Subjects will abstain from alcohol for 24hours prior to ad mission to the CRU and 
continu e abs taining from alcohol until collection of the final PK sample of each stud y 
period.  Subjects may  undergo an alcohol breath test or blood alcohol test at the 
discretion of the investigator .
Subjects wil l abstain from caffe ine-containing products for 24 hours prior to the start 
of dosing until collection of the final PK sample of each study period , and at least 
3 hours prior to ECG evaluations.
Subjects will abstain from the use of tobacco -or nicotine -containing products for 
24hours prior to dosing and during conf inement in the CRU .
4.3.3. Activity
Subjects will abs tain from strenuous exerc ise (eg, heav y lifting, weight training, 
calisthenics, aerobics) for at least 48 hours prior to each blood collection for clinical 
laboratory  tests.  Walking at a normal pa ce wi ll be p ermitted.
4.3.4. Contraception
All fertile male subjec ts and female subjects wh oare of childbearing potential who are, in the 
opinion of the investigator, sexually  active and at risk for pregnancy  with their partner(s)
must agree to use a highly effe ctive method of contraception consistentl yand correctly  for 
the duration of the acti ve treatment period and for at least 28daysafter the last dose of 
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 26investigational product.  The investigator or his or her designee, in con sultation with the 
subject, wi ll confirm t hat the subject has selected anappropriate met hod of contraception for 
the individual subject and his or her partner (s)from the permitted list of contraception 
methods (see below) and will con firm that the subjec t has been instructed in its c onsis tent 
and correct use.  At time points indicated in theSchedu le of A ctivities , the investigator or 
designee will inform the subject of the need to use highl y effective contrace ption consistently  
and correctl y and document the conve rsation and the subject’s affirmation in the subject’s
chart (subjects need to a ffirm their consistent and correct use of at least 1 of the selected 
methods of contraception) .  In addition, the investi gator or designee wi ll instruct the subject 
to cal l immediatel y if the selected contraceptio n method is disco ntinued or if pregnancy  is
know n or suspected in the subject or partner . 
Highl y effective methods of contraception are those that, alone or in com bination, result in a 
failure rate of less than 1% per year wh en used consistently  and corre ctly (ie, perfect use) and 
include the following:
1.Established use of hormonal methods of contraception associated with inhibition of 
ovulation (eg, oral, inserted, injected, implanted, transdermal ),provided the su bject or 
male subject’s female partner plans to remain on t he same treatment through out the 
entire study  and has been using that hormonal contraceptive for an adequate period of 
time to ensure effectiveness .
2.Correctl y placed c opper -containing intrauterine devic e (IUD) . 
3.Male condom or female condo m used WI TH a separate spermicide product (ie, foam, 
gel, film, cream, or suppository ).  For countries where spermicide is not available or 
condom plus spermicide i s not accepted as hi ghly effective contraception, this option 
is not appropriate.
4.Male steri lization with absence of sperm in the post vasect omy ejaculate.
5.Bilateral tubal ligation/bilateral salpingectom y or bilateral tubal occlusive procedure 
(provided tha t occlusion has been confirmed in accordance with the device’s label).
NOTE: Sexual abstinen ce, defined as co mpletel y and persistently refra ining from all 
heterosexual intercourse (including during the entire period of risk associated with the study  
treatm ents) may  obviate th e need for contraception ONLY if this is t he preferred and usual 
lifesty le of the subject .
All sexually  active mal esubjects must agree to prevent potential transfer to and exposure of 
partner(s) to drug through ejaculate b y using a con dom consistently  and correctl y, beginning 
with the first dose of investigational product and continuing for a t least 28 days after the last 
dose of investigational product.
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 274.4.Sponsor ’sQualified Medical Personnel
The contact information for the Sponsor's app ropriately  qualified medical personnel for the 
study isdocume nted in the study  contact list located in the t eam SharePoint site. 
To facilitate access to appropriatel y qualified medical personnel on stud y-related medical 
questions or problems, subjects ar e provided with a contact card. The contact card conta ins, 
ata minimum, protocol and inves tigational produc t identifiers, subject st udy nu mber s, 
contact information for the investigat orsite,and contact details for a contact center in the 
event that the investigat orsite staff cannot be reached to prov ide a dvice o n a medical 
question or problem originating fro m another healthcare prof ession al not involved in the 
subject ’s participation in the study . The contact number can also be used by  investigat or
staff if they  are seeking advice on medical question s or problem s; however, it should be used 
only in the event that the established comm unica tion pathway s between the investigator site 
and the study  team are not available. It is therefore intended to augme nt, but not replace ,the 
established communication pathway s between the investigator site and the study  team for 
advice on medical que stions or problems that may arise during the stud y. For sites other than 
a Pfizer CRU, t he contact number is not intended for use b y the subj ect directly ,and if a 
subject calls that number ,he or she will be dire cted back to the investigator site.
5. STUDY T REATM ENTS
For the purposes of this study , and per International Conference on Harmoni sation ( ICH)
guidelines ,investigati onal product is defined as a pharmaceutical form o f an active 
ingredient or placebo being te sted or used as a reference /comparator in aclinical trial, 
including a product with a marketing authorization when used or assembled (formulated or 
packaged) in a way different from t he approved form, or when used for an unapproved 
indication, or when use d to gain further information about an appr oved use (I CH E6 1.33).
For this study , the investigational product(s) are Azreonam and Avibactam .
5.1.Allocation to Treatmen t
The investigator w ill assign subject numbers to the subjects as they  are screened for the 
study .  This iden tifying number will be re tained throughout the stud y.  All s ubjects enrolled 
will receive 3 days of IV ATM -AVI according to the dose/schedule provi ded in the 
Sectio n 5.4 . 
5.2.Subje ct Compliance
Investigational product willbe ad ministered under the supervision of inv estigator site 
personnel.
5.3.Investigational Product Supplies
5.3.1. Dosage Form and Packaging
Aztreonam an d avibactam will be provided a s sep arate v ials for reconstitution and mi xed 
together in a saline bag for co- admini stration at the appropriate concentration for IVinfusion 
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 28using a standard aseptic IV infusion technique (see Investigational Product Manual 
[IPManual] ).
The identity  ofthe investig ational product is provided in Table 1.
Table 1.Identity of Investigational Product
Investigational ProductsaDosage form  and Strength
Aztreo nam Aztreonam for in jection, powder for solution f or in fusion 2000 m g
Avibactam Avibactam l yophilisate 600 m g/vial Concentrate for so lution for infusion
a.Aztreonam and Avibactam will be supplied by Pfizer Global R&D as separate vials for reconsititution 
and mixed together in a saline bag for co -administr ation at the appropriate concentration for intravenous 
infusion.
5.3.2. Preparation and Dis pensi ng
See the IP manual for instructions on how to prepare the investigational product for 
administration.  Both aztre onam and avibactam v ials are for single- use.  Investiga tional 
product should be prepared and dispensed b y an appropriatel y qualified a nd exp erienced 
member of the stud y staff (eg, ph ysician, nurse, phy sician’s assistant, nurse practitioner, 
pharmacy  assist ant/technician, or p harmacist) as allowed by  local , state, and institutional 
guidance. 
With in this protocol, preparation refers to th einvestigator site activities performed to make 
the investigational product read y for administration or dispensing to the subject/caregiver b y 
qualified staff.  Dispensing is defined as the provision of investigational product, 
concomitant treatments, and accom panying information by  qualified staff member(s) to a 
healthcare provider, subject, or caregiver in accordance with this protocol.  L ocal health 
authority  regulations or investig ator site guidelines may  use a lternative terms for these 
activities.
5.4.Administration
Subjects will receive the loading dose of the investigational product at approximately  
7:30AM(plus or minus 2hours) on Day 1.No fasting is required in respect to dosi ng as 
ATM -AVI is administed in travenously . Fasting will only  be require dprior to safet y 
laboratory  and ECG assessments (see Section 4.3).
On Day 1, the loading dose and extended loadi ng dose will be prepared in 1 infusio n bag.   
The infus ion pump will be programme d to administer the loading dose of ATM -AVI over 
30minutesfollowed by  a rate change to administer the extended load ingdose over 3 hours. 
This is followed by  maintenanc e infusions dosed q6h (normal renal functi on) or q8h (sever e 
renal impairment) accor ding to the treatment schedule described in Table2.  The infusion 
line will be flushed according to local site procedure t o ensure com plete d elivery  of the 
dosing s olution.   The details of the IV infusion will be descri bed in the IP manual.  The start 
and stop time of each infusion will be recorded in the case report form ( CRF ).
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 29Table2.Treatment Sch ema
Day Administr ation 
Start Time 
(2hrs)Cohort 1
(Norm al Rena l Function)Cohort 2
(Severe Renal Impairment)
1 7:30 AM130 min IV loading dose infusion 
(500/167 mg ATM/AVI)130 min IV loading dose infusi on 
(675/225 mg ATM/AVI)1
8:00 AM13 hr IV extended load ing(1500/500 
mg ATM/AVI )13 hr IV extend ed load ing (675/225 
mg ATM/AVI)1
2:00 PM 3 hr IV maintenance infusion q6h 
(1500/500 mg ATM/AVI)
4:00 PM 3 hr IV maintenance infusion q8h 
(675/2 25 mg ATM/AVI)
8:00 PM 3 hr IV maintenanc e infusion q 6h 
(1500/500 mg ATM/AVI)
2 1 2:00 AM 3 hr IV mainten ance infusion q8h 
(675/22 5mg ATM/AVI)
2:00 AM 3 hr IV maintenance infusion q6h 
(1500/500 mg ATM/AVI)
8:00 AM 3 hr IV maintenance infusion q6h
(1500/500 mg ATM/AV I)3 hr IV maintenance infusion q8h
(675/2 25 mg ATM/AVI)
2:00 P M 3 hr IV maintenance in fusion q6h 
(1500/500 mg A TM/AVI )
4:00 PM 3 hr IV maintenance infusion q8h 
(675/225 mg ATM/AVI)
8:00 PM 3 hr IV maintenance infusion q6h 
(1500 /500 mg ATM/AVI)
3 12:00 AM 3 hr IV main tenance infu sion q8 h 
(675/225 mg ATM/AVI)
2:00 AM 3 hr IV mainte nance infusion q6h 
(1500/ 500 mg ATM/AVI)
8:00 AM 3 hr IV maintenance infusion q6h 
(1500/500 mg ATM/AVI)3 hr IV maintenance infusion q8h 
(675/22 5 mg ATM/AVI)
Abbre viation s: ATM/AVI =aztreonam/avibactam ; hr(s)= hour (s); IV = in travenous ; q6h = every 6 hrs; 
q8h=every 8 hrs.
1.Loadin g dose and extended loading dose will be prepared in oneinfusion bag with an infusion rate 
change after the first 3 0 minutes .
5.5.Investigational Product Storage
The invest igator or an approved represen tative, eg, pharmacist, will ensure that all 
investigational products are stored in a secured area with controlled access under required 
storage conditions and in accordan ce with applicable r egulatory  requirements .
Investigat ional p roduct s should be store d in their original cont ainer sand in accordance with 
the label s. 
See the IPmanual for storage conditions of the product once reconstituted for ATM -AVI.
Any storage cond itions stated in the SRSD will be supersede d by thestorage conditions 
stated on the product label. 
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 30Site sy stems must be capable of m easuri ng and documenting (for example, via a log), at a 
minimum, daily  minimum and maximum temperatures for all site stora ge locations (as 
applicable, including froz en, refriger ated, and/or room -temperature products).  This should 
be captured from the time of investigational product receipt throughout the study .  Even for 
continuous- monitoring systems, a log or site procedure that ensures active evaluation for 
excursi ons should be avail able.  The intent is to ensure that the minimum and maximum 
temperature is che cked each business day  to confirm that no excursion occurred since the last 
evaluation and to provide the site with thecapability  to st ore or view the min imum/max imum
temperatur e for all non- working d ays upon return to norma l operations.  The operat ion of the 
temperature -monitoring device and storage unit (for example, refrigerator), as applicable, 
should be regularl y inspected to ensure they aremaintained in working orde r. 
Any excursions from the pr oduct -label storage cond itions should be reported to Pf izer upon 
discovery .  The site should actively  pursue options for returning the product to the storage 
conditions described in the label ing, as soon as possibl e.  Deviations from the storage 
requirements, including any  action s taken, must be documente d and reported to Pfizer . 
Once an excursion is identified, the investigational product must be quarantined and not used 
until Pfizer provide s permission to use the investigati onal pr oduct.  It will not be considered a 
protocol de viation if Pfizer approve sthe use of the investigational product after the 
temperature excursion. Use of the investigational product prior to Pfizer approval will be
considered a protocol deviation. Specifi c details regarding inf ormation the site should report 
for each excursion willbe provided to the site. 
5.6. Investigational Product Accountability
The investigat orsite must maintain adequate reco rds documenting the receipt, use, loss, or 
other disposition o f the investigational p roduct supplies.  All investigational product s will be 
accounted for using a drug accountabilit y form/record. 
5.6.1. Destruction of Investigational Product Supplies 
The sponsor or designee will pr ovide guidance on the d estruction o f unuse d investigational 
produ ct (eg, at the site).   If destruction is authoriz ed to take place at the investigator site, the 
investigator must ensure that the materials are destroy ed in compliance wit h applicable 
environmental regulations, ins titutional p olicy , and any  special instruc tions provided by  
Pfizer ,and all destruction mus tbe adequatel y documented.
5.7.Concomitant Treatment (s)
Health y subjects with normal renal function will abstain from all con comitant treatments
(prescription or over t he counter [ OTC ]) and herbal/dietary  suppl ements during the stud y,
except for acetaminophen 1g/dayand the treatment of AEs.  Limited use of nonprescription 
medications that are not believed to affect subject saf ety or the overall r esults of the study  
may be permitte d on a case-by-case basis foll owing approval by  the sponsor.
For subjects with s evere renal impairment , concomitant medications may  be given if they  are 
considered necessary  for the welfare of study  subjects (e g,standard therapy for underl ying
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 31diseases), are not contraindicated with t he study  drug, and are unlikel y to interfere with the 
PK/PD response of the study  drug. Subjects must be receiving stable doses of these 
concomitant medicatio ns for at le ast 28 daysbefore Screening .  If concomita nt medicatio ns 
are likely to interfere wit h the PK/PD response of the study  drug, they  may  be sub stituted 
with agents that have similar pharmacological effects. 
Use of oral anticoagulants and potent inhibitors of OAT1 and/or OAT3 (e g,probenecid) are 
prohibited in th is stud y for all subjects.
Allconcomitant treatments taken during the study  must be recorded with indication, daily  
dose, and start and stop dates of administration.  All subjects will be questioned a bout 
concomitant treatment at each clinic v isit.
Treatm entstaken within 28 days befo re the first dose of inv estigational product willbe 
documented as a prior treatment .  Treatments taken after the first dose of investigational 
product will be documen ted as concomitant treatment s.
6.STUDY PROCEDURES
6.1.Screening
Subjects will be screened withi n 28 days prior to administration of the investig ationa l 
product to confirm that they  meet the subject selection criteria for the study .  The investigator 
(or an appropria te delegate at the i nvestigator site) will obtain infor med con sent from each 
subject in accordance with the procedures described in theSubject I nformation and Consent
section.  If the time between screening and dosing exceeds 28 days as a result of unexpected 
delay s (eg, delay ed drug shipme nt), then subjects do n ot require rescreening i f the 
Day -2laboratory  results meet the eligibility  criteria.
Two (2) screening visits that are at least 72 hours but no more than 14 days apart a re required 
for this study .
The following p rocedures will be completed for Screening Visit 1:
Obtain written informed consent .
Confirm and d ocument that the subject meets the inclusion/exclusion criteria.
Collect demograph y.
Collect height and weight.
Obta inmedical history , including history  of illegal drug, alcohol ,and tobacco use .
Obta in complete medication history  of all prescriptio nor nonprescription drugs, and 
dietary  and herbal supplements taken within 28 days prior to the planned first dose .
Obtai n single supine BP, PRand temperature .
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 32Conduct fullphysical examination . 
Collect s ingle 12-lead ECG .
Following at least a 4 -hourfast,collect blood and urine specimens forthe following:
Safety  laboratory  tests ;
Urine drug test ;
Serum FSH concentr ation for any female subject who has been amenor rheic f or at 
least 12consecutive months ;
HIV, HepBsAg , andHCVAb testing;
Serum or ur ine beta-human chorionic gonadotropin ( -hCG )level for all female
subject s of childbearing potential;
Confirm highly  effective contraception is being used ;
eGFR assessme nt.  To confir m eligibility , subjects must have stable renal funct ion 
defined as  25% difference between 2measurements of eGFR obtained, from the 
same laboratory , on 2 separate occasions during the Screening period that are at 
least 72 hours but no more t han 14 days apart.  Additionally , differen ce between 
eGFR Screenin g1 value and Day -2value should be 25%.The Day -2eGFR
value will be used for group placement.  The eGFR determination will utilize the 
MDRD formula adjusting for BSA (See Section 3.1).  The CrCL value will be 
recorded at the same time eGFR is determined.
Assess sy mptoms by  spontaneous reporting of adverse events and b y asking the 
subjects to resp ond to a non -leading questio n such as “How do you feel?” 
The followin g procedures will be com pleted for S creening Visit 2:
Following at least a 4-hour fast, collect blood sample for eGFR assessment.
Assess sy mptoms by  spontaneous reporting of adverse even ts and b y asking the 
subject s to re spond to a non -leading question suc h as “How do you feel?” 
To prepare for stud yparticipa tion, subjects will be instructed on the information in the 
Lifestyle Require ments andConcomitant Treatment (s)sections of the protocol.
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 336.2.Study Period
For the stud y period d escribed below, whe n multiple pr ocedures are scheduled at the same 
time point(s) relative to dosing, the following chronology  of events should be adhered to, 
where possible.
ECGs: obtain prior to vi tal sig nmeasurement s and as close as possible to the 
scheduled time, but prior to blood s pecimen collection;
BP/PR: obtain as close as possible to the scheduled time, but prior to blood specimen 
collection;
PK blood spec imens: obtain at the sch eduled time ;
Other procedures: obtain all other procedures as close as possible to the sche duled 
time, but may  be obtained before or after blood specimen collection.
When an IVcatheter is utilized for blood samp le collections, ECGs andvital sign
assessme nts (PR, BP ,and temperature) should be collected prior to the insert ion of the 
cathe ter.  Blood obta ined for PK samples should not be taken from the same IV line 
used to administer study drugs .
6.2.1. Day -2
Subje cts w ill be admitted to the CRU on Day -2.  The f ollowi ng proc edures will be 
completed following admission to the CRU:
Review inclusio nand exclusion criteria.
Review changes in the subject’s medical history  including medication history , illegal 
drug, alcohol and tobacco use since Screening.
Measure weig ht.
Obtain bl ood and urine samples for safet y laboratory tests.  The results must have no 
clinically  significant findings, as judged b y the investigator, in order for a subject to 
be dosed on Day 1.
Collect urine for drug testing.
Collect serum or urine pr egnanc y test for female subjects of childbearing potential. 
Confirm highly  effective contraception is being used.
Conduct fullphysical examination, if deferred from the screening visit .
Assess baseline s ymptoms/AEs.
Aztreonam-Avibactam 
C3601006Final Protocol Amendment 1, 14 July 2021
PFIZER CONFIDENTIAL
Page 34•Assess eGFR: The Day -2 eGFR value will be used for group placement.  To confirm 
eligibility, subjects must have stable renal function defined as ≤25% difference 
between 2 measurements of eGFR obtained, from the same laboratory, on 2 separate 
occasions during the Screening period that are at least 72 hours but no more than 14 days apart.  Additionally, difference between eGFR Screening 1 value and 
Day -2 value should be ≤25%. The eGFR determination will utilize the MDRD
formula adjusting for BSA (See Section 3.1 ).  The CrCL value will be recorded at the 
same time eGFR is determined.
•Standardized meals will be provided as described in Section 4.3 .
•  
6.2.2. Day -1
The following procedures will be completed on Day -1:
•Assess baseline symptoms/AEs.
•Commence prior treatment monitoring.
•Standardized meals will be provided as described in Section 4.3.1 .
Subjects will begin fasting at least 4 hours prior to dosing on Day 1.
6.2.3. Day 1
Prior to dosing , the following procedures will be completed:
•Assess baseline symptoms/AEs.
•Collect single 12-lead ECG measurements prior to insertion of the IV catheter.
•Collect single supine BP and PR and temperature prior to insertion of the IV catheter.
•Collect pre-dose blood sample for PK analysis (within 1hour before start of loading 
dose infusion).
•Monitor prior treatment.
•After all predose procedures have been completed, administer the ATM-AVI 30 min 
loading dose infusion immediately followed by the 3 hour extended loading dose.Loading dose and extended loading dose will be prepared in one infusion bag with an infusion rate change after the first 30 min (see Section 5 andSection 5.4 ). 
•Standardized meals will be provided as described in Section 4.3.1 .C
CCCI
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 35After dosing of loading dose infusion , the foll owing procedures will be completed:
Obtain single 12-lead ECG measurements at 0.5 hour after dosing . (Breakfast should 
not b e given prior to this ECG assessment) .
Assess single supine BPand PRat 0.5 hour after dosing .
Collect blood samples for PKanalysis at 0.5 (within 5 min before the end of th e
loadin g dose IV infusion ) and 3.5 ( within 15 min before the end of extended lo ad IV 
infusion) hours after start of loading dose on Day 1.  Both a venou s blood sample and 
a finger -prick capillary  blood sample will be coll ected (time -matc hed) from subjects
in Cohort 1 (normal renal function) .
Collect maintenance pre -dose (trough) bloodsample for PK anal ysis (within 10min
before start of maintenance dose infusion). Both a venou s blood sample and a finger -
prick c apillary  blood sample will be coll ected (time-matc hed) from subjects in Cohort 
1 (normal renal function) .
Monitor concomita nt treatment .
Administ er the ATM -AVI maintenance dose i nfusion q6h (normal renal function) and 
q8h (severe renal impairment) (see Section 5and Secti on 5.4).
Standardized meals will be provided as described in Section 4.3.1 .
Assess sy mptoms byspontaneous reporting of AEs and by  asking the subjects to 
respond t o a nonlea ding question such as “How do y ou feel?”
6.2.4. Day 2
The foll owing procedures will be completed :
Following at least a 4-hour fast, collect blood and urine specimens for safety  
labora tory tests in the morning ; obtain a fresh 6 mL urine sample for urina lysis.
Assesssingle supine BPand PR in the morning prior to dos ing of m aintenance dose
administered at approximately  8:00 AM.
Collect mainten ance pre -dose (trough) blood sample for P K analysis (within 10 min
before start of each maintenance dose infusion).
Administ er the ATM -AVI maint enance dose infusion q6h (normal renal fun ction) and 
q8h (severe renal impairment) ( see Section 5and Section 5.4).
Monitor concom itant treatment .
Standardized mea ls will be provided as described in Section 4.3.1 .
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 36Asses s symptoms by  spontaneous reporting of AEs and by  asking the subjects to
respond t o a nonleading ques tion such as “How do y ou feel?”
6.2.5. Day 3
The fo llowing procedures will be completed : 
Collect maintenance pre -dose (t rough) blood sample for PK anal ysis (within 10min
before start of each maintenance dose infusion).
Prior to dosi ngof finalmaintenance dose , the following procedures will be c ompleted:
Following at least a 4-hour fast, collect blood and urine specimens f or safety  
laboratory  tests; obtain a fresh 6 mL urine sample for urinal ysis.
Collect single 12-lead ECG measureme nts prior t o insertion of the I Vcatheter (if 
catheter not alrea dy insert ed). 
Collect single supine BP and PR prior to insertion of the IV catheter (if catheter not 
alread y inserted).
Breakfast will be provided prior to administration of the final mainten ance dose but 
after the above p rocedures (safet y laboratory  tests, ECG, B P and PR) have been 
completed. 
Assess sy mptoms by  spontaneous reporti ng of AEs and by  asking the subjects to 
respond to a nonleading question such as “How do y ou feel?” 
Collect main tenance pr e-dose blood sample f or PK anal ysis (within 10minbefore 
start of each maintenance dose infusion).
Each subject will empt y his or her bladder just prior to dosing (Dose give n just prior 
to intensive PK assessment).
Monitor concomitant treatment .
After all predose procedures ha ve been completed, a dminister th e ATM -AVI
maintenance dose ( see Section 5and Section 5.4). 
After dosing offinal m aintenance dose , the following procedures willbe compl eted:
Obtain single 12-lead ECG measurements at 3 hours after dosing.
Assess single supine BPand PRat 3hours after dosing .
Collect venous blood samples for PKanalysis at 2, 3 (wi thin 15 minbefore IV 
infusion s top), 3.25, 3.5 , 3.75, 4, 5, 6, 8, 12 and 16hours after start of maintenance 
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 37dose infusion on Day 3.  Also c ollect a finger -prick capillary  blood sample (time-
matched) from subjects in Cohort 1 (normal renal function) at the fol lowin gtimes: 3
(within 15 min b efore IV i nfusion stop) , 4, 5, and 6 hours after start of maintenance 
dose infusion. Trough sample does not need to be collected for final ma intenance
dose on Day 3 as pre -dose sample will already  be collected as part o f intensiv ePK 
sampling collection.
Collect uri ne over the following intervals: 
0to 2hours after start of maintenance dose on Day 3;
2to 4hours after start of maintenance doseon Da y 3;
4to 6hours after start of maintenance dose on Day 3;
6to 8hours afterstart of maintenance dose on Day 3 (Cohort 2 only ).
Monitor concomitant medication.
Standardized meals will be provided as described in Section 4.3.1 .
Assess sy mptoms by  spontane ous report ing of AEs and by  asking th e subjects to 
respond to a nonleading question such as “How do y ou feel?”
6.2.6. Day 4(end of trial [EOT])
The f ollowing procedures will be complet ed:
Condu ct limited physical examination. 
Perform s ingle 12-lead ECG.
Obtain single supine BP and PR and temperature.
Following at least a 4-hour fast, collect blood and urine specimens for safety 
laboratory  tests; obtai n a fresh 6 mL urine sample for urinal ysis. 
Collect blood samples for PKanalysis at 24hours after start of last maintenance dose 
infusion on D ay3.
Moni tor concomitant treatment .
Assess sy mptoms by  spontaneous reporting of AEs and by  asking the subjects to 
respond to a nonleading qu estion such as “How do y ou feel?” 
Standardized meals will be provided as described inSection 4.3.1 .
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 38Discharge from CRU confinement.
If a subject has an y clinica lly significant, study -related abnormalities at the conclusion of a 
scheduled inpatient portion of the study , the Pfizer medical monitor (or designated 
representative) should be notified and the subject may  be asked to remain in the CRU until 
such abnormal ities are deemed not clinicall y significant, or it is safe for outpatient follow-up.  
If the subject is unable or unwi lling to remain in the CRU and/or whe n outpatient follow -up 
is deemed appropriate, the Pfizer medical monitor (or designated representativ e) should be so 
notified, and the investigat or should make every  effort to arrange follow -up evaluations at 
appro priateintervals to document the course of the abnormalities.
6.3.Follow -up 
6.3.1. Follow -up Contact
Follow -up contact will be completed at least 28 calendar day s and up to 35 calenda r day s 
after t he last administration of the investigational product to capture any  poten tial adverse 
events (see th e Time Period for Collecting AE/SAE I nforma tionsection) and to confi rm 
appropriate contraception u sage (see the Contraception section).  Contact with the s ubjec t
may be done via a phone c all.
6.4.Subje ct Withdrawal
Subjects may withdraw from the study  at any  time at their own request, or they  may  be 
withdrawn at an y time at the di scretion of th e investigator or Sponsor for safety  (see also the
Withdrawal From the Study  Due to Adverse Events (see also th e Subje ct Withdrawal
section) )or, behavioral reasons, or the inability  of the subject to comply  with the
protocol -required schedule of study  visits or procedures at a given study  site.   The ea rly 
termination visit applies only  tosubjects who are randomized and then are prematurel y 
withdrawn from the study.
If a subject does not return for a scheduled visit, every  effort should be made to contact the 
subject.  The investigator or CRU staff shou ldattempt to contact the s ubject twi ce.  After 
2attempts, CRU staff may send a registered l etter.  If no response is received from the 
subject, the subject will be co nsidered lost to follow up.  All attempts to contact the subject 
and information re ceive dduring contact attempts m ust be documented in t he subject’s 
medical record.  In an y circums tance, every  effort should be made to document subject 
outcome, if possible .  The investigator should inquire about the reason for withdrawal, 
request that th e sub ject return for a final visit, if app licable, and follow -up with the subject 
regarding an y unresolved AEs.
It may  be appropriate for the subject to return to the clinic for final safet y assessments to be 
scheduled as earl y as practically feasible following t he decision to withdraw f rom the st udy.  
Subjec ts should be questioned regarding their reas on for withdrawal.  Assessments may  
include:
Full phy sical examination, if there is a new or open AE or clinicall y significant 
abnormal ph ysical finding from the l ast visit;
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 39Supine BP and PRmeasureme nts;
12-lead ECG;
Blood and urine specimens for safety  laboratory  tests;
Blood sample for PK analy sis.
If the subject withdraws fro m the study  and also withdraws consent for disclosure of future 
information, no fur ther evaluations should be perfo rmed and no additional data should be 
collected.  The Sponsor may  retain and continue to use any  data collected before such 
withdrawal of consent.
Subjects who withdraw from the study  may  be replaced at the discretion of the investigator 
upon consultation with the S ponsor.
7.ASSE SSMENTS
Every  effort should be made to ensur e that protocol -required tests and procedures are 
completed as described.  However, it is anticipated that from time to time there may  be 
circumstances outsid e the control of the investigato r that may make it unf easible to perform 
the test.  I n these cases , the investigator must take all steps necessary  to ensure the safet y and 
well-being of the subject.  When a protocol -required test cannot be performed, the 
invest igator will document the re ason for t he missed te st and an y corrective and preventive 
actions that he or she has taken to ensure that required processes are adhered to as soon as 
possible.  The study  team must be informed of these incidents in a timel y mann er.
For samples being coll ected and shipped, det ailed collection, processing, storage, and 
shipment instructions and contact information will be provided to the invest igator site prior 
to initiation of the study .
7.1.Safety
7.1.1. Laboratory Tests
The following safetylaboratory  tests ( Table 3) will be performed at times defined in
Section 6 of this protocol.  Additional laboratory  results may be reported on these samples a s 
a result of the method of anal ysis or th e type of an alyzer used by  the clinical laboratory ; or a s 
derived from calculated values.  These additional tests would not require additional 
collection of blood.  Unscheduled clinical lab oratory  measurements may be ob tained at an y 
time during t he stud y to assess any perceived safety  concerns.
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 40Table 3.Safety Laboratory Tests
Hem atology Chemistry Urinalysis Other
Hem oglobin
Hem atocrit
RBC count
MCV
MCH
MCHC
Platelet count
WBC count
Total n eutro phils 
(Abs)
Eosinophils (Ab s)
Monocyt es (Abs)
Basophils (Abs)
Lymphocytes (Abs)
aPTT
PT
INRBUN/urea and creatinine
Glucose (fasting)
Calcium
Sodium
Potassium
Chloride
Total CO 2(bicarbonate)
AST, ALT
Total bilirubin
Alkaline phosphatase
Uric acid
Albumin
Total proteinpH
Glucose (q ual)
Prote in (qual)
Blood (qual)
Ketones
Nitrites
Leukocyte esterase
Urobilinogen
Urine bilirubin
MicroscopyaFSH
Urine drug screen ing
β-hCGb
Hepatitis B surface antigen
Hepatitis C core antibody
Human immunodeficiency 
virus (HIV)
Additional Tests
(Neede d for Hy’s Law)
AST, ALT (repeat)
Total bilirubin (repeat)
Albumin (repeat)
Alkaline phosphatase 
(repeat)
Direct bilirubin
Indirect bilirubin
Creatine kinase
GGT
PT/INR
Total bile acids
Acetaminophen drug 
and/or protein adduct 
levels
a.Only if urine d ipstick is positive for blood, protein, nitrites or leukocyte esterase .
b.Serum or urine -hCG for female subject s of childbearing potent ial.
The m inimum requirement for drug screening includes cocaine, tetrah ydrocannabinol
(THC ), opiates /opioids, benzodiaz epines ,and amphetamines.
Subjects may  undergo random urine drug testing at the discretion of the investigator.   
Drug testing conducted prior to dosing must be negative for subjects to receive 
investigational product.
7.1.2. Pregnancy Tes ting
For female subjects of childbe aring potential, a serum or urine pregnancy  test, with 
sensitivity  of at least 25 mIU/mL, will be performed at S creening and at adm ission on 
Day -2.
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 41A negative pregnancy testresult is required before the subject may receive the ATM -AVI.  
Pregna ncy tests will also be done whenever 1menstrual cy cle is missed during the active 
treatment period (or when potential pregnancy  is oth erwise suspected) . Pregnancy  tests may  
also be repeated if requested by institutional re view bo ards ( IRBs)/ethics committees ( ECs)
or if required b y local regulations.
Urine pregnancy  tests must be sensitive to at least 25 mIU/mL andwillbe conducted wit h the 
test kit provided by  the investigator sitein accord ance with instructi ons provided in its 
packa ge insert.  Subjects who have missed a menstrual period or who sho w an indeterminate
or positive result on the urine test may  not further progress in the study until pregnancy  is 
ruled out using further diagnostic testing (eg, a negative quant itative serum pregnancy test 
conducted at a certified laboratory ).
In the case of a positive confirmed pregnancy , the subject will be withdrawn from
administration of inves tigational product and from the study .
7.1.3. Physical Examinations
Physical ex aminations m ay be conduct ed by a ph ysician, trained ph ysician's assistan t, or 
nurse practit ioner as acceptable according to local regulation.  A full phy sical e xamination 
will include head, ears, eyes, nose, mouth, skin, heart and lung examinations, ly mph nodes, 
and gastrointestinal, muscul oskeletal, and neurological sy stems.  The limited or abb reviated 
physical examination will be focused on general appearance, therespiratory  and 
cardiovascular s ystems, andsubject -reported s ymptoms.
For measuring weight, a scale wit h appropriate range and resolution is used and must be 
placed on a stable, flat surface. Subjects must remove shoes, bulky  layers of clothing, and 
jackets s othat only  light clothing remains.  They  must also remove the contents of their 
pocket s and remain still during measureme nt of weight. 
Height measurement only at screening when full phy sical examination is performed .
7.1.4. Blood Pressure and Pulse Rat e
BPand PRwill be measured at times specified in Section 6of thi s protocol.  Additional 
collection times, or changes to collection times, of BPand PRwill be permitted, as 
necessary , to ensure appropriate collection of safety  data.
Supine BPwill be measured with the subject’s arm su pported at t he level of t he heart and 
recorded to the nearest mm Hgafter approximately  5 minutes of rest .  The same arm 
(preferabl y the dominant arm) will be u sed throughout the study . BPshould not be taken 
from the arm with an IVinfusion.  Subjects should b e inst ructed not to speak dur ing 
measurements.
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 42The same properl y sized and calibrate d BPcuff will be used to measure BPeach time.  The 
use of an automa ted device for measuring BP and PRisacceptable ; however, when done 
manually , PRwill be measur ed in the br achial/radial artery  for at least 30 seconds.  When the 
timing of these measure ments coincides with a blood collection, BP and PRshould be 
obtained prior to the nominal ti me of the blood collection.
7.1.5. Temperature
Temperature will be measured temporall y or orally.  No ea ting, drinking ,or smoking is 
allowed for 15 minutes prior to the measurement.
7.1.6. Electrocardiogram 
Twelve ( 12)-Lead ECGs should be coll ected at times specified in Section 6 ofthisprotocol.
All schedul ed ECGs should be performed after the subject has rested quietly  for at least 
10 minutes in a supine position. 
To ensure saf ety of the subjects, a qualified indiv idual at the investigator site will make 
comparisons to ba seline measu rements.  If the QTc interval is increased b y 45msec from 
the baseline, or an absolute QTc value is 500msec for any  scheduled ECG, then 
2additi onal ECGs will be collected, approxima tely 2to 4 minutes apart, to confirm the 
original measure ment.  If ei ther of the Q Tc values from these repeated ECGs remains above 
the threshold val ue (ie, is 45msec from the baseline , or is 500msec), then a single ECG 
must be repeated at least hourly until QTc values from 2 successive ECGs fall below the 
threshold value that trigge red the re peat measurement.
If QTc values remain 500msec (or 45msec from the baseline) for greater than 4 hours (or 
sooner ,at the discretion of the investigator), or QTc intervals get progressively  longer, the 
subject should undergo cont inuous ECG monitoring. A cardiologist should be consulted if 
QTc intervals do not return to less than 500 msec (or to <45 msec above the baseline) after 
8 hours of monitoring (or sooner, at the discretion of the investigator).
In some cases, i t may  be app ropriate to r epeat abno rmal ECGs to rule out improper lead 
placement as contrib uting to the ECG abnormality .  It is important that leads are placed in the 
same positions each time in ord er to achieve precise ECG recordings.  If a machine- read Q Tc 
value is prolonged, as defined a bove, repeat measurements may  not be necessary  if a 
qualified medical provider ’s interpretation determines that the QTc value s are in the 
acceptable range.
7.2.Pharmac okinetics
7.2.1. Plasma for Analysis of Aztreonam -Avibactam
During all study periods, venous blood samples ( 2mL) to provide approximately 1.0mLof
plasma for PK analy sis will be collected into appropriately labeled tu bes containing Sodium 
Fluoride/ Potassium Oxalate (grey  top) at times specified in Secti on 6of the protocol.  
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 43On Day  1 and Day 3, cap illary  blood microsamples ( appro ximately  65 µL) to provide 30-35
µLof plasma for PK analysis will be collected from a finger -prick into capillary  tubes 
containing Sodium Fluorid e/Potassium Ox alate at times specified in Section 6of the protocol
(subjects with normal renal function only).Capillary  sampl ingwill be from the second and
third finger (ie,ringandmiddle f inger) after proper preparation and puncture of the skin.  
Detail s of t he procedure for capillary sampling are provided in the Lab oratoryManua l. After 
collection, c apillary  tubes will be placed in toappropriately  labeled holder sfor processing . 
Sample h andling det ails for both venous and capillary  blood are provided in the Laboratory  
Manual.
The actual times may  change , but the numb er of samples will remain the same.  All efforts 
will be made to obtain the PKsamples at the exact nominal time r elative t o dosing.  
However, samples obtained within 10% of the nominal ti me (eg, within 6 minutes of a 
60-minute sample) from dosing will not be captured as a protoco l deviation, as long as the 
exact time of the sample colle ction is noted on the source do cument an d data coll ection tool
(DCT) (eg,case report form [ CRF ]).
Sampl es will be analy zed using a validated anal ytical method in compli ancewith Pfizer & 
vendor st andard operating procedures (SOPs) .
The PK samples must be processed and shipped as indic ated in the instruct ions provided to 
the investigator site to maintain sam ple integrity .  Any deviations from the PK sample 
handling proced ure(eg,sample collection a nd processing steps, interim storage or shipping 
conditions) , including any actions taken , must bedocumented and reported to the sponsor.
On a case -by-case basis , the sponsor may  make a determination as to whether sample 
integ rityhas been compromised.  Any deviation from the specified sample handling 
procedure resulting in compromised sampl e integri tywill be considered a protocol deviation.
As part of understanding the PK of the investigational product, samples may be used fo r
metabolite identification a nd/or evaluation of the bioanaly tical method , as well as for other 
internal exploratory  purposes.  These dat a will not be included in the clinical study  report 
(CSR).
7.2.2. Urine for Analysis of Aztreonam -Avibactam
Urine will be col lected at times specified inSection 6of the protocol.  Each subject wil l 
empty  hisor her bladder just prior to the last main tenance dose being administered at 
approximately  8:00 AMon Day 3.  Each subject will b e inst ructed to void into the collection 
container at the end of each collection period.
Sample s will be analy zed u sing a validated anal ytical method in compliance with Pfizer & 
vendor SOPs.
The PK samples must be processed and shipp ed as indicated in the instr uctions provided to 
the investigator site to maintain samp le integrity .Any deviations f rom the P K sample 
handling procedure (eg, sample collection and processing steps, interim storage or shipping 
conditions) , including any ac tions taken, must be documented and reported to the sponsor.
Aztreonam-Avibactam 
C3601006Final Protocol Amendment 1, 14 July 2021
PFIZER CONFIDENTIAL
Page 44On a case-by-case basis, the sponsor may make a determination as to whether sample 
integrity has been compromised.  Any deviation from the specified sample handling procedure resulting in compromised sample integrity will be considered a protocol deviation.
As part of understanding the PK of the investigational product, urine samples may be used 
for metabolite identification and/or evaluation of the bioanalytical method.  These data will be used for internal exploratory purposes and will not be included in the CSR.
7.3. Blood Volume
The total blood sampling volume for individual subjects in this study is approximately 86 mL
for subjects with normal renal function and 81 mL for subjects with severe renal impairment.  The actual collection times of blood sampling may change.  Additional blood samples may be taken for safety assessments at times specified by Pfizer, provided the total volume taken during the study does not exceed 550 mL during any period of 60 consecutive days.
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 CCI
CCI
Aztreonam-Avibactam 
C3601006Final Protocol Amendment 1, 14 July 2021
PFIZER CONFIDENTIAL
Page 45 
 
 
 
 
 
 
 
8. ADVERSE EVENT REPORTING
8.1. RequirementsThe table below summarizes the requirements for recording safety events on the CRF and for 
reporting safety events on the Clinical Trial (CT) Serious Adverse Event (SAE) Report Form to Pfizer Safety.  These requirements are delineated for 3 types of events: (1) SAEs; (2) non-serious adverse events (AEs); and (3) exposure to the investigational product under study during pregnancy or breastfeeding, and occupational exposure. 
Safety Event Recorded on the CRF Reported on the CT SAE 
Report Form to Pfizer Safety Within 24 Hours of Awareness
SAE All All
Non-serious AE All None
Exposure to the investigational product under study during pregnancy or breastfeeding, and occupational exposureAll (regardless of whether 
associated with an AE), except occupational exposureExposure during pregnancy, 
exposure via breastfeeding, occupational exposure (regardless of whether associated with an AE)
All observed or volunteered events regardless of treatment group or suspected causal relationship to the investigational product(s) will be reported as described in the following paragraphs.CCI
CCI
CCI
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 46Events listed in the table above th at require reporting to Pfizer Safet yon the CT SAE Report 
Form within 24 hours of awareness of the ev ent by  the investigator are to be reported 
regardless of whether theevent is determined by the investigator to be related to an 
investigational product u nder study.  I n particular, if the SA E is fatal or life -threatening, 
notification to Pfizer Safety  must be made immediately , irrespective of the extent of available 
eventinformation.  This time fra me also applies to additional new (follow- up) information on 
previously  forwarded reports.  I n the rare si tuation that the investigator does not become 
immediat ely aware of the occurrence of an event, the investigator must re portthe event 
within 24 hours after learning of it and document the time of his/her firs t awareness of the 
event.
For each ev ent, the in vestigator must pursue and obtain adequate information both to 
determine the outcome and to assess whether it meets the criteria for cl assification as an SAE 
(see Section 8.2.3 ).  In addition, the investigator may be requested b y Pfizer Safety to obtain 
specific follow -up information in an expedited fashion.  Thi sinformation is more detail ed 
than that recorded on the CRF .  In general, this will i nclude a description of the eve nt in 
sufficient detail to allow for a complete medical assessment of t he case and independent 
determination of possible causality .  Any information relevant to the ev ent, such as 
concomitant medications and illnesses, must b e provided.  In the case of a s ubject death, a 
summary  of available autopsy  findings must be submitted as soon as possible to Pfizer 
Safety .  Any  pertinent additional information must be reported on the CT SAE Report Form; 
additional source documents (eg, medical records, CRF, laborator y data ) are to be sent to 
Pfizer Safety  ONLY upon request.
As part of ongoing safet y reviews conducted b y the sponsor, an y non -serious A E that is 
determined b y the spo nsor to be serious will be reported by  the sponsor as an S AE.  To assist 
in the determina tion o f case seri ousness, further information may  be requested from the
investigator to provide clarity  and understanding of the event in the context of the clinical 
study.
8.1.1. Additional Details on Recording Adverse Events on th e CRF
All events detailed in th e tabl e above wil l be recorded on the AE page(s) of the CRF.  I t 
should be noted that the CT SAE Report Form for reporting of SAE inform ation is not the 
same as the AE page of the CRF.  When the same data are collected, the f orms must be 
completed in a con sistent manner.  AEs should be recorded using concise medical 
terminolo gy and the same AE term should be used on both the CRF and the CT SAEReport 
Form for reporting of SAE information.
8.1.2. Eliciting Adverse Event Information
The investigator is to record on the CR F all direc tly observed AEs and all AEs spontaneousl y 
reported b ythe study  subject .  In addition, each study subject will be questio ned about the 
occurrence of AEs in a non- leading manner.
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 478.1.3. Withdrawal From the Study Due to Adverse Events (see also th e Subje ct 
Withdrawal section)
Withdrawal due t o AEs should be distinguished from withdrawal due to other causes , 
according to the definition o f AE noted below, and recorded on the CRF. 
When a subject withdraws from the study  because of an SAE, the SAE must be recorded on 
the CRF and reported, as appr opriate, on the CT SAE Report Form, in accordance with the 
Requirements section above.
8.1.4. Time Period for Collecting AE/SAE Informa tion
The time period for active ly eliciting and collecting AEs and SAEs (“active collection 
period”) f or each subject begins from the time the subject provides informe d consent, which 
is obtained be fore the subject’s participation in the study  (ie, before undergoing any  
study -related pr ocedur e and/or re ceiving investigational product), through and includin g a 
minimum of 28 calendar days; after the last administration of theinvestigational product.
For subjects who are screen failures, the active collection period ends when screen failur e 
status is deter mined.
8.1.4.1. Reporting SAEs to Pfizer Safety
All SAEs occurr ing in a subject during the active collection period are reported toPfizer 
Safety  on the CT SAE Report Form.
SAEs occurring in a subject after the active collection period has ended ar e reported to Pfizer 
Safety  if the investigator becomes aware of them; at a minimum, all SAEs that the 
investigator believes have at lea st areasonable possibility  of being related to investigational 
product must be reported to Pfizer Safety .
Follow up by  the in vestigator continues throughout and after the active collection p eriod and 
until the event or its sequelae resolve or stabilize at a level acceptable to the inve stigator, and 
Pfizer concurs with that assessment.
8.1.4.2. Recordi ng Non -serious AEs and SAEs on the CR F
During th e active collection period, both non -serious AEs and S AEs are recorded on the 
CRF.
Follow -up by  the investigator may  berequired until the event or it s sequelae resolve or 
stabilize at a level acceptable to t he investigator, and Pfizer con curs w ith that assessment.
8.1.5. Causality Assessment
The investigator’s asse ssment of causalit y must be provided for all AEs (serious and 
non-serious); the investigator must record the causal relationship on the CRF, and report su ch 
an assessment in accordance with t he SAE repo rting requirements, if applicable.  An 
investigator’s causalit y assessment is the determination of whether there exists a reasonable 
possibility  that the investigational product caused or contributed to an AE ; generall y the facts 
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 48(evidence ) or a rguments to suggest a causal relationship should be provided.  If the 
investigator does not know whether or not the investigationa l product caused the event, the n 
the event will be handled as “related to investigational product” for reporting purpose s, as 
defined b y the sponsor.  If the investigator's causality  assessme nt is “unknown but not 
related” to investigational product, this should be clearl y documented on study  records. 
In addition, if the investigator determin es that an SAE is associated wi th stu dy procedur es, 
the investigator must record this causal relations hip in the source documents and CRF, and 
report such an assessmen t inthe dedicated section of t he CT SAE Report Form and in 
accordance with the SAE repor ting requirements.
8.1.6. Sponsor’s Re portin g Requireme nts to Regulatory Authorities
AE reporting, including suspected unexpected serious adverse reactions, will be carried out 
in accordance with applicable local regulations.
8.2.Definitions
8.2.1. Adverse Events
An AE is a ny untoward medical occurrence in a s tudy subjec t administered a product or 
medical device; the event need not necessaril y have a causal relationship with the treatmen t 
orusage.  Examples of AEs include, but are not limited to: 
Abnormal test findings;
Clinically  significant signs and sy mptoms;
Changes in phy sical examination findings;
Hypersensitivity ;
Progression/worsening of underl ying disease ;
Drug abuse;
Drug depe ndency.
Additionally , AEs may  include signs and s ymptoms resulting from:
Drug overdose;
Drug withdrawal;
Drug misuse; 
Drug in teractions;
Extravasation;
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 49Exposure during pregnancy  (EDP);
Expos ure via breastfeeding;
Medication error;
Occupational exposure.
8.2.2. A bnormal Test Findings
Abnormal objective test findings should be recorded as AEs when an yof the following 
conditions ar e met:
Test result is associated with accompan ying symptoms; and/or
Test result requires additional diagnostic testing or medical/surgi calintervention; 
and/or
Test r esult leads to a change in stud y dosing (outside of an y protocol -specified dose 
adjustments) or discontinuation from the study, significant additional concomita nt 
drug treatment, or other therap y; and/or
Test result is considere dto be an AE b y the investi gator or sponsor.
Merel y repeating an abnormal test, in th e absence of an y of the above c onditi ons, does not 
constitute an AE.  An y abnormal test result that is determined to be an error does not require 
recording as an AE.
8.2.3. S erious Adverse Events
A serious adverse event is any  untoward medical occurrence at any  dose that:
Results in death;
Is life-threatening (immediate risk of death);
Requires inpatient hospital ization or prolongation of existing hospitalization;
Results in pers istent or significant disabi lity/incapacity  (substantial disruption of the 
ability  to conduct normal life functions);
Resul ts in conge nital anomaly /birth defect.
Or that is considered to b e:
An important medical event.
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 50Medical and scientific judgment is exercised in determining wheth er an event is an important 
medical event.  An important m edical event may  not be immedia tely life-threate ning and/or 
result in death or hospitalization.  However, if it is determined that the event may  jeopardize 
the subject ormay require intervention to prevent one of the other AE outcomes, the 
important medic al event should be reported as seriou s.
Examples of such events are intensive treatment in an emergenc y room or at home for 
allergic bronchospasm; blood dy scrasias or convulsions that do not result in hospitalization; 
or development of drug dependency  or drug abuse.
8.2.4. Hospitalization
Hosp italiz ation is de fined as an y initial admission (even less than 24 hours) in a hospital or 
equivalent healthcare facility , or any  prolon gation of an existing admission .  Admission also 
includes transfer within the hospital to an acute/intensive care unit ( eg, fr om the psy chiatric 
wing to a medical floor, medical floor to a co ronary  care unit, or neurological floor to a 
tuberculosis unit). Anemergency  room visit does n ot necessaril y constitute a hospitalization; 
however, the event leading to the emergency  room v isit is ass essed for medical importance.
Hospitalization does not include the following:
Rehabilitation facilities;
Hospice facili ties;
Respite care (eg, caregiv er relief);
Skilled nursing facilities;
Nursing homes;
Same- day surgeries (as outpatient/ same -day/ambulato ry procedures).
Hospitalization or prolongation of hos pitalization in the absence of a precipitating clinical 
AE is not initself an SAE.  Examples include: 
Admission for treatment of a preexisting condition not associated with the 
development of a new AE or with a worsening of the preexisting condition (eg, for 
workup of a persistent pretreatment laboratory  abnormality );
Social admission (eg, subject has no place to sleep);
Administrative admission (eg, for yearly physical examination);
Protocol- specified admission during a stud y (eg, for a procedure require d by the study  
protocol);
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 51Optional admission not associated with a precipitating clinical AE (eg , for elective 
cosmetic surgery );
Hospitalization for obse rvation without a medical AE;
Preplan ned treatme nts or surgical procedures.  These should be noted in the baseline 
documentation for the entire protocol and/or for the individual subject;
Diagnostic and therapeutic noninvasive and invasive procedures, such as surgery , 
should not be repo rted a s SAEs.  However, the medical condition for which the 
procedure w as performed should be reported if it meets the definition of an SAE .  For 
example, an acute app endicitis that begins during the reporting period should b e 
reported if the SAE requireme nts ar e met, and the resulting appendectomy  should be 
recorded as treatment of the AE.
8.3.Severity Assessment
If required on the AE page of the CRF, the investigator will use the adjectives MILD, 
MODERATE, or SEVERE to describe the maximum intensity  of the AE .  For purposes o f 
consistency , these intensity  grades are defined as f ollows:
MILD Does not interfere with subject's usual function.
MOD ERATE Interferes to some extent with subject's usual function.
SEVERE Interferes sign ificantl y with subject's usual functi on.
Note t he distinction between the severit y and the seriousnes s of an AE.  A severe event is not 
necessarily  an SAE.  For example, a headache may be severe (i nterferes significantly  with 
the subject's usual function) but would not be classified as serio us unless i t met one of the 
criteria for SAEs, listed above.
8.4.Spec ial Situations
8.4.1. Potential Cases of Drug- Induced Liver Injury
Human s exposed to a drug who show no sign of liver injury  (as determined by  elevations in 
transaminases) are termed “tolerato rs,” w hile those who show transient liver injury , but adapt 
are termed “adaptors.”  In some subjects, transaminase elevations are a harb inger of a more 
serious potenti al outcome.  These subjects fail to adapt and therefore are "susceptible" to 
progressive and se rious liver injury , commonly  referred to as drug -induced liver in jury 
(DILI).  Subjects who experience a transaminase elevation ab ove 3 times the upper limit of 
normal ( ×ULN) should be monitored more frequently  to dete rmine if they are an “adaptor” 
or are “susceptible.”
In the majority  of DILI cases, elevations in aspa rtate aminotransferase (AST) and/or alanine 
aminotransferase (ALT ) precede total bilirubin (TBil i) elevations (>2 ×ULN) by  several 
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 52days or weeks.  The increase in TBili ty picall y occur s whil e AST/ALT i s/are still elevated 
above 3 ×ULN (ie, AST/AL T and TB ili values will be elevated within the same lab sample).  
In rare instances, b y the time TBili e levations are detected, AST/ALT values might have 
decrease d.  This occurrence is still re garded as a potential DILI.  Therefore, abnormal 
elevations in either A ST OR AL T in addition to TBili that meet the criteria outlined be low
are considered potential DI LI (assessed per Hy ’s law criteria) cases and should alway s be 
considered important medic al eve nts, even b efore all other possible causes of liver injury  
have b een excluded.
The threshold of laboratory  abnormalities for a pot ential DILI case depends on the subject’s 
individual baseline values and underl ying condi tions.  Subjects who present wi th the
following laboratory  abnormalities should be evaluated further a s potential DILI (Hy ’s law) 
cases to definitivel y determine the e tiology of the abnormal laborat ory values:
Subjects with AST/AL T and TBili baseline value s within the normal range who 
subsequently  prese nt with AST OR AL T values >3 ×ULN AND a TBili value 
>2 × ULN with no evidence of hemol ysis and an alkaline phosphatase value 
<2×ULN or not availabl e.
For subjects with baseline AST OR ALT ORTBili values a bove the ULN, the 
following thr eshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:
Preexistin g AST or ALT baseline values ab ove the normal range: AST or ALT 
values >2 times the baseline values AND >3 ×ULN; or >8 ×ULN (whichever is 
smaller).
Preexisting values of TBili above the nor mal range: TBili level increased from 
baseline value b y an amount ofat least 1 × ULN or if the value reaches 
>3×ULN (whichever is smaller).
Rises in AS T/AL T and TBili separated b y mo re tha n a few wee ks should be assessed 
individually  based on clinical j udgment; an y case where uncertainty  remains as to whether it 
represents a potential Hy’s law cas e should be reviewed with the sponsor.
The subject should return to the investigator site and be evaluate d as soon as possible, 
preferabl y within 48 hours from awareness of the abnormal results.  This evaluation should 
include laboratory  tests, detailed history , and physical assessment. 
In addition to repeating measurements of AST and AL T and TBil i, laborato ry tests should 
include albumin, creatine kinase (CK), direct and indirect bilirubin, gamma -glutam yl 
transferase (GGT), prothrombin time (PT)/internat ional normalized ratio (INR), total bile 
acids, alkaline p hosphatase and acetaminophen dr ug and /or protein adduct levels.  
Consideration should also be given to drawing a separate tube of clotted blood and an 
anticoagulated t ubeof blood for further testing, as needed, for further contemporaneous 
analyses at the time of the recognized initial abnorm alities to determine etiology .  A detailed 
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 53history , including rel evant information, such as review of ethanol, acetaminophen (eith er by 
itself or as a coformulated product in prescription or over- the-counter medications), 
recreational drug, supplemen t (her bal) use an d consumption, family  history , sexual history , 
travel history , history  of contact with a jaundiced person, surgery , blood transfusion, history  
of live r or allergic disease, and potential occupational exposure to chemicals, should be 
collec ted.  Further testing for acute hepatitis A, B, C, D, and E infection a nd liver imaging 
(eg, biliary  tract) may  be warranted. 
All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
TBili e levation defined above should b e cons idered pote ntial DILI (Hy ’s law) cases if no 
other reason for the live function test ( LFT)abnormalities has y et been found.  Such
potential DILI (Hy’s law) case s are to be reported as SAEs, irrespective of availability
of all the results of the inve stigat ions perfor med to determine etiology of the LFT 
abnormalities.
Apotential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable in vestigations have been received and have excluded an alter native etiology .
8.4.2. Exposure to th e Inve stigational Product During Pregnancy or Breastfeeding, and 
Occupational Exposure
Exposure to the investigational product under stu dy during pregnancy  or breastfe eding and 
occupational exposure are reportable to Pfizer S afety  within 24 hours of invest igator
awareness.
8.4.2.1. Exposure During Pregnancy
For both unapproved/unlicen sed products and for marketed products, an exposure during 
pregna ncy(EDP) occurs if:
A female b ecomes, or is found to be, pregnant either while receiving or having been 
exposed (eg, be cause of treatmen t or environmental exposure) to the investigational 
product; or the female becomes or is found to be pregnant after dis continuing and/or 
being exposed to the investigational product;
An example of environment al exposure would be a case inv olving direct con tact 
with a Pfizer product in a pregnant woman (eg, a nurse reports that she is pregnant 
and has been exposed to chemot herapeutic products).
A male ha s been exposed (eg, because of treatment or environmental exposure) to the 
investigationa l prod uct prior t o or around the time of conception and/or is exposed 
during his partner’s pregnancy .
If a subject or subject’s partner becomes or is found to be pregn ant during the subject’s 
treatment with the investigationa l product, the investigator mus t report this inf ormation to 
Pfizer Safety  on the CT SAE Report Form an d an EDP supplemental form, regardless of 
whether an SAE has occu rred.  In addition, the investi gator must submit information 
regarding environmental exposure to a Pfizer product in a p regnan t woman (eg , a subject 
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 54reports that she is pregnant and has been exposed to a cy totoxic product by inhalation or 
spillage) to Pfiz er Safety  using the EDP supplem ental form.  This must be done irrespective 
of whether an AE has occurred and within 24 hours of awareness of the exposure.  The 
information submitted should include the anticipated date of delivery  (see below for 
information related to termination of preg nancy ).
Follow -up is conducted to obtain general information on the pregnancy  and its outcome f or 
all EDP reports with an unknown outcome.  The investigator will follow the pregnancy  until 
completion (or until pregnancy  termi nation) and notify  Pfizer Safet y of the outcome as a 
follow -up to the initial EDP supplem ental form.  In the case of a l ive bi rth, the st ructural 
integrit y of the neonate can be assessed at the time of birth.  In the event of a termination, the 
reason(s) f or termination should be specif ied and, if clinically  possible, the structural 
integrit y of the terminated fetus should be ass essed by  gross visual inspection (unless 
pre-procedure test findi ngs are conclusive for a congenital anomal y and the findings are 
reported).
If the outcome of th e pregnancy  meets the criteria for an SAE (ie, ectopic pre gnancy , 
spontaneous abortion, i ntraut erine fetal demise, neonatal death, or congenital anomal y [in a 
live-born bab y, a terminated fetus, an intrauterine fetal demise, or a neonatal death]), the 
investigator should follow the procedures for reporting SAEs.
Additional information about pr egnanc y outcomes that are reported to Pfizer Safet y as SAEs 
follows: 
Spontaneous abortion includes miscarriage and missed abortion;
Neonatal deaths that occur within 1month of birth should be reported, without regard 
to causality , as SAEs.  In addition, infant deaths aft er 1month should be reported as 
SAEs when the investigator assesses the infant death as related or possibly  related to
exposure to the investigationa l product. 
Additional information regarding the EDP may  be requested b y the sponsor.  Further 
follow -up of birth outcomes will be handled on a case- by-case bas is (eg, follow -up on 
preterm infants to identify developmental de lays).  In the case of paternal exposure, the 
investigator will provide the subject with the Pregnant Partner Release of Infor mation Form
to deliver to his partner.  The investigator must doc ument in the source documents that the 
subject was given the Preg nantPartner Release of Informa tion Form to provide to his 
partner.
8.4.2.2. Exposure During Breas tfeeding
Scenarios of exposure during breastfeeding must be reported, irrespective of the presence of 
an associated SAE, to Pfizer Safet y within 24 hours of the invest igator’s awareness, using the 
CT SAE Report Form.  An exposure during breastfeeding repor t is not created when a Pfizer 
drug s pecifically approved for use in breastfeeding women (eg, vitamins ) is administered in 
accord with authorized use.  However, if the infant experiences an SAE asso ciated with such 
a drug’s administration, the SAE is repor ted together with the exposure during breastfeeding.
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 558.4.2.3. Occupational Exposure
An occupational exposure oc curs when, during the performance of job duties, a person 
(whethe r ahealthcare professional or otherwise) gets in unplanned direct contact with the 
produ ct, which may  or may  not lead t o the occurrence of an AE.
An occupational exposure is reported to Pfiz er Safety  within 24 hours of the investigator’s 
awareness, using the CT SAE Report Form, regardl ess of whether there is an associated 
SAE.  Since the info rmation does not pertain to a subject enrolled i n the study , the 
information is not recorded on a CRF; however, a copy  of the completed CT SAE Report 
Form is maintaine d in the investigator site file.
8.4.3. Medication Errors and Lack of Efficacy
Other exposures t o the investigational product u nder study  may  occur in clinical trial settings, 
such as medication err ors and lack of efficacy .
Safety Event Recorded on the CRF Repor tedon the CT SAE 
Report Form t o Pfizer 
Safety Within 24 Hours of 
Awareness
Medication e rrors and lack 
of efficacy  All(rega rdless of w hether 
associated with an AE) Only  if associated with an 
SAE 
8.4.3.1. Medication Errors
Medication errors may  result from the administration or consumption of the investigational 
product b y the wrong subject, or at the wrong time, or at the wron g dosa ge strength .
Medication errors include :
Medication errors involv ing subject exposure to the investigational product;
Potential me dication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the participating subject.
Such medication errors occurring to a stud y participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified immediately .
Whether or not the medica tion error is accompanied by  an AE, as determined by  the 
investigator, the medication error is recorded on the medication e rror page of the CRF and, i f 
applicable, an y associated AE(s), serious and non -serious, are recorded on an AE page o f the 
CRF. 
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 56Medic ation errors should be reported to Pfizer Safety  withi n 24 hours on a CT SAE Report 
Form only when associated with an S AE.
8.4.3.2. Lack of Efficacy 
Lack of e fficacy  in an approved indication should be reported as an SAE to Pfizer Safety .
9.DATA ANALYSIS/ STATISTICAL METHODS
Detailed methodology  for summary  and statisti cal anal yses of the data collected in this study  
is outlined here andfurther detailed in a s tatistical analysis plan (SAP) , which will be 
maintained by  the sponsor.  The SAP may modify what isoutlined in the protocol where 
appropriate ; however, any  major modifications of the primary  endpoint definition sor their
analyses will also be reflected in a protocol amendment.
9.1.Sample Size Determination
Approximate ly 6subjects will be enrolled into e ach the nor malrenal function group and the 
severe renal impairme nt group as described in Sectio n 3.1.  The sample size is based on 
recommendations from th e “food and drug administration (FDA )Guidance f or 
Industry  -Pharmacokinetics in Patients with I mpair ed Renal Function -Study  Design, Data 
Analy sis, and Impact on Dosi ng and Labeling” .10  Subjects who discontinue from the stud y 
before complet ing al l assessments may  be replaced at the discretion of the investigat or and 
Sponsor.
A total of 42 capillary  microsamples (7 sample s per subject) will be collected from subjects 
in the normal renal function group at pre -specif ied time points on Day  1 and Day 3as 
describ ed in Section 6.2. The sample size of capillary  micro samples time -matched to venous 
samples is based on recommendatio ns from the “ Land O’Lakes Microsampling workshop
organized by  the American Association of Pharmaceutical Scientists (AAPS) ”.11Allowing 
for up to a 10% diffe rence between capillary andvenous plasma concentrations, between 30 
to 40 data points at minimum are recommended where the intra -sample variability  (%CV) is 
<20%. Precision (%CV) is ≤10% for concentrations spanning t he cali bration curve of t he
dual-analyte bioanal ytical assay  valid ated for simultaneous anal ysis of a ztreo nam and 
avibactam plasm a concent rations from a single microvol ume plasma sample .
9.2.Efficacy Analysis
Efficacy  anal ysisis not applicable to this study . 
9.3.Phar macokinetic Analysis
The PK conc entration population is defined as all subjects treated with study  drug who have 
at least 1 ATM and AVI concentration measurement.
The PK parameter anal ysis population is defined as all subjects treated with stud y drug who 
have at least 1 of the PK paramet ers of interest.
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 57Analy sis of var iance (ANOVA) will be used to compare the natural log transformed 
AUC 0-24,ssand C maxbetween the normal renal function group and the severe renal impair ment 
group . The geometric least square s mean point estimate and the associated 90% confidence 
interval s (CIs) for the difference of each co mparison will be estimated. 
Aztreonam and avibactam PK parameters AUC 0-24,ss, Cmax, AUC 0-τ, Tmax, C, t½, CL, CL r, VZ, 
Vss, Ae0-τ, Ae0-τ% will be summarized de scriptively b y group.
Box plots of mean, median and indiv idual subject parameters will be made across both
groups for AUC 0-24,ss,CmaxandC.  Concentrations wil l be listed and summari zed 
descriptivel y by PK sampling time and group.  Summary profiles (mea ns and medians) of the 
concentration -time data will be plo tted across different groups.  Individual subject 
concentration -time profiles will be also presented .  For summary  statistics a nd summary  plots 
by sampling time, the nominal PK sampling time will be used; for individual subject plots by  
time, the actual PKsampling time will be used.
Attainment of stea dy state will be evaluated by  a graphical presentation of pre- infusion
concentra tion (trough) values on Day s 1-3.
9.3.1. Plasma
PK parameters of aztreonam and avibactam following multiple dose administration will be 
derived from the venous plasma concentration -time profiles as follows:
Param eter Definition Method of Determ ination
AUC 0-24,ss Total daily a rea under the plasma 
concentration -time profile from time 0
to24 hours at steady -stateNormal renal function (Cohort 1): 
AUC 0-× 4 (= 6 hours)
Severe rena l impairment (Cohort 2):
AUC 0-×3(= 8 hours)
AUC 0- Area under the plasma 
concentration -time profile from time 0
to to the time of the end of the dosing 
interval ()bLinear/Log trapezoidal rule
Cmax Maximum plasma con centration Observed directly fr om data
Tmax Time for C max Observed directly from d ata as time of first 
occurre nce
C Observed concentration at the end of 
the dosing interval ( )bObserved directly from data
t½aTerm inal elimination half -life Log e(2)/k el, where k elis the terminal ph ase 
rate constant calc ulated by a linear 
regression of the log -linear 
concentrat ion-time curve.  Only those data 
points judged to describe the terminal 
log-linear decl inewill be used in the 
regression
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 58Param eter Definition Method of Determ ination
CL Clearance Dose/AUC 0-
Vss Appar ent volume of dist ribution at 
steady -stateVolume of distribution at steady state is 
calculated as : V ss= CL ×MRT
Mean residence time (MRT) is calculated 
as:MRT = AUMC 0-/AUC 0--(infusion 
time/2)
Area under the first moment curve from 0
time to (AUMC 0-) is calculated as: 
AUMC 0-= ((t × C est1*)/kel) + (Cest1*/kel2)    
1Cest= e(-KEL × Tlast) ×KELC 0
Vz Apparent volume of distribution
during terminal phaseDose/(AUC 0-× k el)
a.If data permit .
b.= 6 hours for normal renal function (Coho rt 1) and 8 hours for severe re nal impairment (Cohort 2).
Actual PK sampling times and non- compartmental metho ds will be used in the derivation of 
PK parameters.
Capillary Plasma Microsamples
To determi neconcordance/comparabilit yof capillary  microsample plasma concentrations
with venous plasma concentrati ons, X- Y andBland- Altman (B -A)scatter plots with limits of 
agreement (LoA) for a precision assessment will be used.
The Bland -Altman scatterplot will include the difference of the 2 measurements divided by  
themean ( %difference)for each sample on the vertical axis and the average of the 2
measurements on th e horizon tal axis. Three horizontal reference lines willbesuperimposed 
on the scatterplot -one line at the average perce ntdifference between the measurements and
lines to mark the upper and lowe r limits of 95% CI. The same plot will be generate d for 
difference of the 2measurements (vertical axis ) and the average of the 2 measurements on 
the horizon tal axis.
If the 2methods are comparable, then %differences/ differences should be negligible, with 
the mean of the differences close to 0, and show no sy stematic variation with the mean of the 
2measurements.
Venous and capil laryobserved plasma concentrations, individual subject differences and % 
differences ofconcentrations willbe listed and sum mariz ed descriptively  by PK sampling 
time.
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 599.3.2. Urine
UrinePK parameters of aztreonam and avibactam following multiple dose administration of 
ATM -AVI will be derived as follows:
Param eter Definition Method of Determ ination
Ae0- Total amount of unchanged drug excr eted in the 
urine over the do sing i nterval ( )aSum of amount excreted for each 
collection period.
Ae0-% Total amount of unchang ed drug excreted in the 
urine over the dosing interval ( )a, expressed as 
percent of dose100× (Ae 0-/Dose)
CL r Renal clear ance Ae0-/AUC 0-
a.= 6 hour s for norm al renal f unction (Cohort 1) and 8hours for severe renal impairment (Cohort 2).
9.4.Safety Analysis
AEs, ECGs, BP , PR, and safet y laboratory  data will be reviewed and summarized on an 
ongoing basis during the s tudy to evaluate the safety  of subject s.  An y clinical laboratory , 
ECG, BP, and PRabnormalities of potential clinical concern will be descr ibed.  Safet y data 
will be presented in tabular and/or graphical format and summarized descriptively , where 
appropri ate.
Medi cal history  and phy sical exam inatio ninformation collected during the cou rse of the 
study  will be considered source data and will n ot be required to be reported, unless otherwise 
noted.  However, an y untoward findings identified on phy sical and/or neurolog ical
examination s conducted during the active collection period will be captured as AEs, if those 
findings meet the definition of a n AE. Data collected at screening that are used for 
inclusion/exclusion criteria, such as laboratory  data, ECGs, and vital s igns, will be 
considered sour ce dat a, and will no t be required to be re ported, unless otherwise noted.  
Demographic data collected at Screening will be reported .
9.4.1. Electrocardiogram Analysis
Changes from baseline for the ECG parameters QT interval, heart rat e, QTc interval, PR 
interval ,and Q RS interval wi ll be summarized by  treatment and time.
The number (%) of subjects with maximum po stdose QTc values and maximum increases 
from baseline in the following categories will be tabulated b y treatment: 
Safety QTc Assessment
Borderline (mse c) Prolonged (m sec)
Absolute value 450-480 >480
Absolute change 30-60 >60
In addition, the num ber of subjects with corrected and uncorrected QT values >5 00 msec will 
be summarized.
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 609.5.Data Monitoring Committee 
This study  will not use a data monitorin g comm ittee (DMC ).
9.6. Interim Analysis 
No fo rmal interim anal ysis will be conducted for this study .  How ever, as this is an 
open -label study ,the sponsor may  conduct unblinded reviews of the data during the course of 
thestudy  for the purpose of safet y asses sment, facilitating dose-escalation decisi ons, 
facilitating PK/PD modeling, and/or supporting clinical development.
10.QUALITY CONTROL AND QUALITY ASSURANCE
Pfizer or its agent will conduct periodic monitoring visits during stud y conduct for studies 
conduct ed at non- Pfizer inv estigator sites ,to ensu re that the protocol and Good Clinical 
Practices ( GCPs) ar e being followed.  The monitors may  review source documents to 
confirm that the data recorded on CRFs /DCT sare accur ate.  T heinvestigator and institution
will allow Pfizer m onitors /auditors or its agents and appropriate regulatory  authorities direct 
acces s to source documents to perform this verification.   This verification may  also occur 
after stud y completion.
During study  conduct and/or after study  completion , the investig ator site may  be subje ctto 
review b y the IRB/EC , and/or to quality  assurance audi ts performed b y Pfizer, or companies 
working with or on behalf of Pfizer, and/or to inspection by  appropriate regula tory 
authorities.
The investigator(s) will n otify  Pfizer or its agents immediate lyof any  regulatory  inspection 
notification in relation to the study . Furthermore, the investigator will cooperate with Pfizer 
or its agents to prepare the investigator site for the i nspection and will allow Pfiz er or its 
agent, whe never feasible, to be present during the inspection. The investigator site and 
investigator will promptly resolve an y discrepancies that are identified between the stud y 
data and the subject’s medi cal recor ds.  The investigator will pr omptl yprovide copie s of the 
inspection fi ndings to Pfizer or its agent.  Before response submission t o the regulatory 
authorities, the investigator will provide Pfizer or its agents with an opportunity  to review 
and c omment on responses to any such findin gs.
For studies conducted at non -Pfizer in vestigator sites, it is important that the investigator(s) 
and their relevant personnel are available during the monitoring visits and possible audits or 
inspections and that s ufficient time is devoted to the proce ss. 
11. D ATA HANDLING AND RECORD KEEPING
11.1. Case Report Forms/ Data Collection Tools/ Electronic Data Record
As used in this protocol, the term CRF /DCT should be understood to refer to either a paper 
form or an electronic data record or both, depending on the data colle ction method u sed in 
this study .
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 61A CRF/DCT is required and should be completed for each included subject.  The completed 
original CRFs /DCTs are the sole propert y of Pfizer and should not be made available in an y 
form to t hird parties, except for auth orized representatives of Pfizer or appropri ate regulatory  
authorities, without written permission fro m Pfizer.   The investigator shall ensure that the 
CRFs/DCTs are securel y stored at the study site in en crypted elect ronic and /or paper form 
and will be pa ssword protected or secured in a locked ro omto prevent access by  
unauthorized third parties.
The inve stigator has ultimate responsibility  for the collection and reporting of all clinical, 
safet y,and laboratory  data e ntered on the CRFs /DCTs and an y other data c ollection form s 
(source documents) a ndensuring that they  are accurate, authentic/original, attr ibutable, 
complete, consistent, legible, timely (contemporaneous), enduring ,and available when 
required.  The CRFs/DCTs must be signed b y the investigator or b y an authorize d staff 
member to atte stthat the data contained on the CRFs/DCTs are true.  Any  corrections to 
entries made in the CRFs /DCTs orsource documents must be dated, initialed ,and explained 
(if necessar y) and should not obscure the original entry .
In most case s the source documents are the hospital or the phy sician's chart.  I n these cases,
data collected on the CRFs/DCTs must match those charts. 
In some cases, the CRF /DCT may also serve as the source d ocument. In these cases, a 
document should be available a t the investigator site andat Pfizer that clearly  identifies those 
data that will be recorded on the CRF /DCT ,and for which the CRF /DCT will stand as the 
source document.
11.2. Record Retention
To enabl e evaluat ions and/or inspections/ audit s from regulatory  authorities or Pfizer, t he
investigator agrees to keep records, including the identi ty of all participating subjects 
(sufficient information to link records, e g,CRFs /DCTs and hospital records), all o riginal 
signed informed consent docume nts, c opies of all C RFs/DCTs, safety  repor ting forms, source 
documents, detailed records of treatment disposition, and adequate documentation of relevant 
correspondence (e g,letters, meeting minutes, and telephone call reports) .  The records should 
be reta ined b y the investig ator according to the ICHguidelines , according to local 
regulations, or as specif ied in the clinical study  agreement (CSA) , whichever is longer.   The 
investigator must ensure that the records conti nue to be stored securel y for so long as the y are 
retained.
If the investigator becomes unable for any  reason to continue to retain study  records for the 
required period (e g,retirement, relocation), Pfizer should be prospectivel y notified.  The 
study  records must be transferred to a designee accept able to Pfizer , such as another 
investigator, another institution, or to an independent third pa rty arranged by Pfizer. 
Investigator records must be kept for a minimum of 15 years after completion or 
discontinua tion of t he study  or for longer if req uired by applicable local regulations.
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 62The investigator must obtain Pfizer's written permission befor e disposing of an y records, 
even if retention requirements have been met.
12.ETHICS
12.1. Institutional Review Board/Ethics C ommittee
It is the responsibility  of the investigator to h ave prospective approv alof the study  protocol, 
protocol amendments, informed cons entdocuments, and other relevant documents, 
eg,recruitment advertisements, if applicable, from the I RB/EC.  All corresponde nce with the 
IRB/EC should be retained in the inv estigator file .  Copie s of IRB/EC approvals should be 
forwarded to Pfizer.
The onl y circumstance in which an amendment may  be initiated prior to IRB/EC approval is 
where the change is necessary  to eliminate apparent immediate hazards to the subjects.  In 
that event, the investiga tor must notify  the IRB/EC and Pfizer in writing immediate ly after 
the implementation.
12.2. Ethical Conduct of the Study
The study  will be conducted in accordance with the protoco l, legal and regulatory  
requirements, andthe general prin ciples set forth in th e International Ethical Guidelines for 
Biomedical Research I nvolving Human Subjects (Council for International Organizations of 
Medical Sciences 2002), ICH G uideline for Good C linical Practice , and the Declaration of 
Helsinki.
In addi tion, the study  will b e conducted in accordance with the protocol, the I CH guideli ne 
on GCP, and applicable local regulatory  requirements and laws.
12.3. Subject Information and Consent
All parties will comply  with all applicable laws, includ ing la ws regarding t he implementation 
of organizational and technical measures to ensure protection of subject personal data.   Such 
measures will include omitting subject names or other directl y identifiable data in an y 
reports , publications, or other disc losure s, except wher e required b y applicab lelaws. 
The personal data will be stored at the study  site in en crypted electronic and/or paper form 
and will be password protected or secured in a locked room to ensure that only authorized 
study  staff have acce ss.  T he study  site will implement appropr iate technical and 
organizational measures to ensure that th e personal data can be recovered in the event of 
disaster.  In the event of a potential personal data breach, the st udy site shall be responsible 
for dete rminin g whether a pe rsonal data breach has in fact occurred and, if so, providing 
breach notifications as required by  law.
To protect the rights and freedoms of natural persons with regard to the processing of 
personal data, when study  data are compiled fo r tran sfer to Pfizer and other authorized 
parties, subject names will be removed and will be replaced by a single, specific, numerical 
code, based on a numbering s ystem defined by  Pfizer .  All other identifiable data transferre d 
to Pfizer or other authoriz ed par ties will be i dentified by  this sing le, subject -specific code.   
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 63The investigator site will maint ain a confidential list of subjects who participated in the 
study , linking each subject’s numerical code to his or her actual identity .  In case of data 
transfe r, Pfizer will maintain high standar dsof confidentiality  and protection of subjects’ 
personal data consistent with the Clinical Study  Agreement and applicable privacy  laws.
The informed consent documents and an ysubject recruitment materials must be in 
compliance with ICH GCP, local regulat ory requirements, and legal requirements, including 
applicable privacy  laws.
The informed consent documents used during the informed consent process and any  subject 
recruitment material s must be reviewed and approv ed by  Pfizer, approved by  the IRB/EC 
befor e use, and available for inspection.
The investigator must e nsure t hat each study subject is fully  informed about the nature and 
objectives of the stud y, the sharing of data re lating to the study  and possible risks assoc iated 
with par ticipation, including the risks associated with the processing of the subject’s pe rsonal 
data.  The investigator further must ensure that each study  subject, is fully  informed about his 
or her right to access and correct his or her pers onal d ata and to wit hdraw consent for the 
processing of his or her personal data.
The investigator, or a person designated by  the investigator, will obtain written informed 
consent from each subject before any  study -specific ac tivity  is performed , unless a waive r of 
informed consent has been grant edby an IRB/EC .  The investigator will retain the original of 
each subject's signed consent document.
12.4. Reporting of Safety Issues and S erious B reaches of the Protocol or ICH GCP
In the event of an y prohibition or r estric tion imposed ( ie, clinical hold) b y anapplicable 
regulatory  authorit y in any  area of the world ,or if the investigator is aware of any  new 
information that might influence the evaluation of the benefits and risk s of the investigational 
product, Pfiz er sho uld be informe d immediately . 
In add ition, the investigator will inform Pfizer immediately  of an y urgent safet y measures 
taken b y the investigator to protect the study subjects against an y immediate hazard, and o f 
any serious breaches of this protocol or of ICH GCP that the investigator beco mes aware of.
13.DEFINITION OF END OF TRIAL
13.1. End of Trial in the United States 
Last subject last visit ( LSLV)is defined as the date the investigator reviews the last subject’s 
final safet y data and determines that no furth er evaluation is required for the subj ect to 
complete the trial.
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 6414.SPONSOR DISCONTINUAT ION CRITERI A
Premature termination of this study  may  occur because of a regulatory  authority  decision, 
change in opinion of the IRB/EC, or investigational product safety problems, or at the 
discretion of Pfi zer.  In addition, Pfizer retains the right to discontinue d evelopment of 
PF-06947387 at an y time.
If a stud y is prematurel y terminated, Pfizer will promptly  notify  the investi gator.  A fter 
notification, the investigator must contact all participating subjects and the hospital pharmacy  
(if applicable) within 7 days.  As directed by  Pfizer, all study  materials must be collected and 
all CRFs /DCTs completed to the greatest extent p ossible.
15.PUBLICATION OF STUDY RESULTS
15.1. Commu nication of Re sults by Pfizer
Pfizer fulfills its commitment to publicly  disclose clinical study results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov) , the European Clinica l Trials 
Database (EudraCT), and/or www.pfiz er.com, and ot her public registries inaccordance with 
applicable local laws/regulations.
In all cases, stud y results are reported b y Pfizer in an objective, accurate, balanced, and 
complete manner and are reported regardless of the outcome of the st udy orthe country  in 
which the study  was conducted.
www.clinicaltrials.gov
Pfizer posts clinical tri al US B asic Results on www.clinicaltrials.gov for Pfizer -sponsored 
interventional studies (conducted in patients) that evalua te the safety and/or efficacy of a 
Pfizer product , regardless of the ge ographical location in which the study  is conducted.  US 
Basic Results are submitted for posting within 1 year of the primary  completion date (PCD) 
for studies in adult populations or w ithin 6 months of the PCD forstudi es in pediatri c 
populations.
PCD is defined as the date that the final subject was examined or r eceived an intervention for 
the purposes of final collection of data for the primary  outcome, whether the clinical study
conc luded according to the prespe cified protocol or w as terminated.
EudraCT
Pfizer posts European Union ( EU)Basic Results on EudraCT f or all Pfizer -sponsored 
interventional studies that are in scope of EU requirements.  EU Basic Results are submitted
for post ing within 1 year of the PCD for st udies in adult populations or within 6months of 
the PCD for studies in pediatric populations.
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 65www.pfizer.com
Pfizer posts public disclosure s ynopses (CSR synopses in which any  data that could be used 
to identify individu al patients have been removed ) on w ww.pfizer.com for Pfizer -sponsored 
interventional studies at the same time the US Basic Results document is posted to 
www.clinicaltrials.gov .
15.2. Publications by Investigators
Pfizer supports the exercise of academic freedom and has no objection to publ ication by  the
princ ipal investigator (PI)of the results of the study  based on information collected or 
generated b y thePI, whether or not the results are favorable to the Pfizer product.  However, 
to ensure against inadverte nt disclosure of confidential infor mation or unpr otected 
inventions, th e investigator will provide Pfizer an opportunity  to review any  proposed 
publication or other t ype of disclosure of the results of the study  (collectively , “publication”)
befor e it is submitted or otherwise disclosed.
The investigator will provide any publ ication to Pfizer at least 30 days before it issubmitted 
for publication or otherwise disclosed.  If an y patent action is required to protect intellectual 
propert y rights, theinvestig ator agrees to delay  the disc losure for a period not to exceed an 
addit ional 60 days.
The i nvestigator will, on request, remove an ypreviously  undisclosed confidential 
information before disclosure, except for an y study -or Pfizer product -related informati on 
necessary  to the appropria te sci entific presen tation or understandin g of the study  results .
If the study  is part of a multi cente r study , the investigator agrees that the first publication is 
to be a joint publication covering all investigator sites, and that an y subsequent publicat ions 
by the PIwill reference that primary publication .  However, if a joint manuscript has not 
been s ubmitted for publication within 12 months of completion or termination of the study  at 
all participating sites, the investiga tor is free to publish separa tely, subject to the other 
requirements of this section .
For all publications relating to the study , the institution will comply  with recognized ethical 
standards concerning publications and authorship, including Secti on II - “Ethical 
Considerations in the Condu ct and Reporti ng of Research” of the Uniform Requirements for 
Manuscripts Submitted to Biomedica l Journals, http://www.icmje.org/index.html#authorship,
established by  the International Committee of Medical Journal Editors .
Publication of study  result s is a lso provided f or in the C SAbetween Pfizer and the 
institution.  I n this section entitled Publications by  Investigators, the defined terms shall have 
the meanings given to them in the C SA.
If the re is any  conflict between th e CSA and an y attachments to it, the terms of the CSA 
control.  If there is an y conflict between this protocol and the CSA, this protocol will control 
as to any  issue regarding treatment of study  subjects, and the CSA will cont rol as to all other 
issues.
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 6616. R EFEREN CES
1. Lucasti C, Popescu I, Ramesh MK, et al. Comparative study  of the efficacy  and safet y of 
cefta zidime/avibactam plus Metronidazole versus meropenem in the treatment of 
complicated intra -abdominal infections in h ospitaliz ed adults: results of a rando mized,
double -blind, Phase II trial. J Ant imicrob Chemother 2013;68(5):1183 -92.
2. Magiora kos AP, Sriniva san A, Carey  RB, et al. Multidrug resistant, extensively  
drug-resistant and pandrug -resistant bacteria: an international expe rt proposal for 
interim stand ard de finitions for acquired resistance. C lin Microbiol I nfect 2012; 18: 
268–81.
3. Innovative Medicines Initiativ. http://www.imi.europa.eu/ (last accessed: 20 February 
2018).
4. Innovative Medicines Initiative ND4BB Topic 5: Clinic al development of antibacterial 
agents for Gram n egative antibiotic res istant pathogens. 
https://www.imi.europa.eu/sites/default/files/archive/uploads/documents/9th_Call/ND4
BB_Topic5.pdf (last accessed: 20 February  2018) .
5. AZACTAM(US prescribing informat ion). Bristol -Myers Squibb; 2 013.  
http://package inserts.bms.com/pi/pi_az actam.pdf .Accessed 20 February  2018.
6. El Guinaidy  MA, Naw ishy S, Abd El Bary  M, et al. Single -dose pharmacokinetics of
aztreonam in health y volunteers and renal failure pati ents. J C hemother 
1989;1(3):164 -9.
7. Mihindu J C, Scheld WM, Bolton ND, et al. Phar macokinetics of aztreonam in patients 
with various degrees of renal d ysfunction. Antimicrob Agents Chemother 
1983;24(2):252 -61.
8. AVY CAZ(US prescribing information). Allergan; 2018 .  
https://www.allergan.com/assets /pdf/a vycaz_pi.
9. ZAVI CEFTA(summary  of pro duct characteristics). Pfizer; 2017.  
http://www.ema.europa. eu/docs/en_GB/document_library /EPAR_ -
_Product_I nformation/human/004027/WC500210234.pdf .
10. Guidance for Industry : Pharmacokineti cs in patients with impaired renal function   
Study design, data anal ysis, and impact on dosing and labeling. Draft FDA Guidance, 
March 2010.
11. Wickr emsinhe ER, Ji QC, Gleason CR, Anderson M, Booth BP.  Land O’Lakes 
Workshop on Micros ampling: Enabling Broade r Adoption.  The AAPS Journal
2020; 22:135 .
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 67Appendix 1.Abbre viations 
The followin g is a list of abbreviations that may  be used in the protocol.
Abbreviation Term
14C carbon -14
%CV coefficient of variation as percentage
AAPS American Association of Pharma ceutical Scientists
Abs absolute
ADM E absorption, distri bution, metabolism, and e xcretion
AE adverse event
Ae0- total amount of unchange d drug excreted in the urine over dosin g 
interval
Ae0-% Total amount of unchanged drug excreted in the urine over dosing 
interval , expressed as percent of dose
ALT alanin e aminotransferase
ANOVA analysis of variance
aPTT activated p artial thromboplast in time
AST aspartate aminotransferase
ATM aztreonam
ATM -AVI aztreonam -avibactam
AUC area under the curve
AUC 0-24,ss Total daily  area under the plasma concentration tim e profile from 
time 0to 24 hours at steady -state
AUC 0- area under the plasma con centration- time profile from time 0to to 
the time of the end of the dosing interval ( )
AUC ss area under the curv eat stea dy-state
AVI avibactam
B-A Bland-Altman
BA bioavailability
BE bioequivalence
-hCG beta-human chorionic gonadotropin
BMI body  mass index
BP blood pressure
bpm beats per minute
BSA body  surface area
BUN blood urea nitrogen
C-G Cockcroft -Gault
CAZ ceftazidime
CAZ -AVI ceftaz idime -avibactam
CI confidence interval
cIAI complicated intra -abdominal infections
CK creatine kinase
CL Clearance
Aztreonam-Avibactam 
C3601006Final Protocol Amendment 1, 14 July 2021
PFIZER CONFIDENTIAL
Page 68Abbreviation Term
CL r renal clearance
Cmax maximum observed plasma concentration
Cmin minimum observed plasma concentration
CO2 carbon dioxide (bicarbonate)
CrCL creatinine clearance
CRF case report form
CRU clinical research unit
CSA clinical study agreement
CSR clinical study report
Cτ observed concentration at the end of the dosing interval ( τ)
CT threshold concentration
CT clinical trial
CTA clinical trial application
CTCAE Common Terminology Criteria for Adverse Events
CTX-M cefotaximase -M
CV% coefficient of variation
DCT data collection tool
DILI drug-induced liver injury
DMC data monitoring comm ittee
EC ethics committee
ECG electrocardiogram
EDP exposure during pregnancy
EDR extemporaneous dispensing record
eGFR estimated glomerular filtration rate
ESBL extended spectrum β-lactamase
ESRD end-stage renal disease
EU European Union
EudraCT European Clinical Trials Database
FDA food and drug administration
FSH follicle-stimulating hormone
GCP Good Clinical Practice
GGT gamma-glutamyl transferase
GFR glomerular filtration rate
hCG human chorionic gonadotropin
HepBsAg hepatitis B surface antigen
HCVAb hepatitis C antibody
HIV human immunodeficiency virus
IB Investigator’s Brochure
ICH International Conference on Harmonisation
IND investigational new drug applicationCCI
C
CI
Aztreonam-Avibactam 
C3601006Final Protocol Amendment 1, 14 July 2021
PFIZER CONFIDENTIAL
Page 69Abbreviation Term
INR international normalized ratio
IP manual investigational product manual
IRB institutional review board
IRC internal review committee
IRT interactive response technology
IUD intrauterine device
IV intravenous
KPC Klebsiella pneumonia carbapenemase
LFT liver function test
LSLV last subject last v isit 
MBL metallo-βlactamase
MCH mean corpuscular hemoglobin
MCHC mean corpuscular hemoglobin concentration
MCV mean corpuscular volume
MDR multidrug resistant
MDRD Modification of Diet in Renal Disease
MIC minimum inhibitory concentration
N/A not applicable
NDM New Delhi Metallo- β-lactamase
OAT organic anion transporter
OTC over the counter
OXA Oxacillinase
PCD primary completion date
PD pharmacodynamic(s)
pH potential of hydrogen
PI principal investigator
PK pharmacokinetic(s)
PK/PD pharmacokinetic/pharmacodynamic
PR pulse rate
PT prothrombin time
PTA probability of target attainment
q6h every 6 hours
q8h every 8 hours
QTc corrected QT
QTcF QT interval corrected by Fridericia’s formula
qual qualitative
RBC red blood cell
SAC Scientific Advisory Committee
SAE serious adverse event
SAP statistical analysis planCCI
CCI
Aztreonam -Avibactam 
C3601006
Final Protocol Amendment 1 , 14 July 2021
PFIZER CONFIDENTIAL
Page 70Abbreviation Term
SCr serum creatini ne
SD standard deviation
SOP standard opera ting procedure
SRSD single reference safet y document
t½ terminal elimination ha lf life
TBili total bilirubin
THC tetrah ydrocannabinol
Tmax Time for C max
ULN upper limit of normal
US United States
VIM Verona Integron encoded metallo --lactamas e
Vss apparent volume of distribution at steady -state
Vz apparent volume of distribut ion during terminal phase
WBC white blood cell